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Abstract
Treatment of metastatic melanoma with tumor reactive T cells (adoptive T cell
therapy, ACT) is a promising approach associated with a high clinical response
rate. However, further optimization of this treatment modality is required to
increase the clinical response after this therapy. ACT in melanoma involves an
initial phase (pre-REP) of tumor-infiltrating lymphocyte (TIL) expansion ex vivo
from tumor isolates followed by a second phase, “rapid expansion protocol”
(REP) generating the billions of cells used as the TIL infusion product. The main
question addressed in this thesis was how the currently used REP affected the
responsiveness of the CD8+ T cells to defined melanoma antigens. We
hypothesized that the REP drives the TIL to further differentiate and become
hyporesponsive to antigen restimulation, therefore, proper cytokine treatment or
other ways to expand TIL is required to improve upon this outcome.

We evaluated the response of CD8+ TIL to melanoma antigen restimulation using
MART-1 peptide-pulsed mature DC in vitro. Post-REP TILs were mostly hyporesponsive with poor proliferation and higher apoptosis. Phenotypic analysis
revealed that the expression of CD28 was significantly reduced in post-REP TILs.
By sorting experiment and microarray analysis, we confirmed that the few CD28+
post-REP TILs had superior survival capacity and proliferated after restimulation.
We then went on to investigate methods to maintain CD28 expression during the
REP and improve TIL responsiveness. Firstly, IL-15 and IL-21 were found to
synergize in maintaining TIL CD28 expression and antigenic responsiveness
during REP. Secondly, we found IL-15 was superior as compared to IL-2 in
supporting the long-term expansion of antigen-specific CD8+ TIL after
restimulation.

-viii-

These results suggest that current expansion protocols used for adoptive T-cell
therapy in melanoma yield largely hyporesponsive products containing CD8+ T
cells unable to respond in vivo to re-stimulation with antigen. A modification of
our current approaches by using IL-15+IL-21 as supporting cytokines in the REP,
or/and administration of IL-15 instead of IL-2 after TIL infusion, may enhance the
anti-tumor efficacy and long-term persistence of infused T cells in vivo.

-ix-

Chapter 1

General background
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1. Adoptive cell therapy
1.1 T cell differentiation and anti-tumor T cell response

Naïve T cells are activated upon encounter with cognate antigen and proper
costimulation, in presence of different cytokines. For optimal T cell activation,
three critical steps need to occur [1]: 1) TCR ligation with antigen presented by
MHC class I or II molecules on APC; 2) Presence of costimulation on APC
binding to their receptors on lymphocytes, 3) Permissive biochemical
environment manifested as the proper signaling pathways. For example, T cell
anergy, which occurs in the absence of proper costimulation, arises from the
disproportional signaling events between highly activated calcium/NFAT versus
diminished or defective RAS/MAPK pathways [2, 3]. The anergized T cells also
have upregulated diacylglycerol kinases (DGKs), early growth response 2 (EGR2), EGR-3, E3 ubiquitin ligases gene related to anergy in lymphocytes (GRAIL),
and Casitas B-cell lymphoma-b (Cbl-b) [4, 5]. Any problems that occur at the
above steps may result in either apoptosis or non-responsiveness of the T cells
(also called “anergy”) [1, 6]. Among these, the positive or negative costimulation
(herein named costimulation or coinhibition) compose signal two, whereas
antigen presentation by APCs provides signal one.

Upon activation, for example with viral infection, antigen specific T cells can
robustly expand and form a large pool of reactive T cell population. They migrate
to tissue sites and exert their cytolytic (CD8+) or helper (CD4+) functions. After
successfully battling with danger, the effector T cell pool contracts dramatically,
up to 95% reduction. The remaining antigen specific T cells form a long-term
memory population that can be reactivated more rapidly than the original naïve T
cells. The maintenance of T cell memory has been shown to be antigenindependent but cytokine-dependent [7, 8].

-2-

It is intriguing, as well as important, for vaccine design, to discern how memory T
cells differentiate, especially in the CD8+ T cell lineage. Most of the knowledge on
phenotypic markers and factors regulating T cell activation and memory induction
are from studies done on models of viral infection. Many of these concepts are
applicable to human tumor immunology. As described early, naive CD8+ T cells
experience three phases of responses [9-11]: initial activation and expansion,
contraction and memory persistence. For the origin of memory T cells, there are
mainly two models: “the linear differentiation model” and “the signal strength
differentiation model” [12]. Specifically, Douglas Fearon and others propose
memory T cells develop from effector T cells [13, 14]. Recently, a reporter mouse
model was developed in which the Granzyme B promoter was controlled by Cremediated recombination [14]. Observations from this study showed that CD8+ T
cells are activated and differentiated into effector T cells, following which a
portion of the effector cells survive to form the memory T cell pool [14]. This
result supports the linear differentiation model. On the other hand, Antonio
Lanzavecchia, Leo Lefrançois and others, emphasized that the initial signal
strength may dictate different fates of T cell differentiation immediately after initial
activation [10, 15-17]. For example, in an in vivo study, the frequency of naive T
cell precursor has a profound influence over the CD8+ memory T cells develop
pathway [17]. The data suggested the limiting antigen availability could enhance
memory T cell development. Leo Lefrançois and colleagues recently suggested a
novel model, named “early cell fate determination” model [7], to reconcile the two
models described above (Fig. 1-1). After initial activation, CD8+ T cells progress
into early effector stage, phenotypically homogeneous and expressing Granzyme
B and IFN-γ. As the development of immune response, these early effector T
cells undergo significant heterogeneity based on the signal strength (antigen,
cytokines, and others) they receive. IL-7Rα and KLRG-1 were two markers found
to be useful to distinguish memory T cell precursors.
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Fig. 1-1. “Early cell fate determination” model for CD8+ memory T cell
development.
Naive CD8+ T cells get activated and become CD127- KLRG1- early effectors.
This is reflecting the linear differentiation model and the corresponding
supporting data. Upon further antigen experience, early effector cells could be
differentiated along different pathways, depending on the antigen signal
stimulation strength. This is in accordance with the “signal strength differentiation
model”. High antigen load and/or inflammatory cytokines produce terminallydifferentiated CTL, that are CD127- KLRG1+ CD62L-. This model predicts that
memory-precursor effector cells are generated by weaker antigen load, including
TCM (CD127+ KLRG1- CD62L+) and TEM (CD127+ KLRG1- CD62L-). Over
longer periods of time, the memory population is either maintained or
differentiated into CTL.
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Adapted from Ann N Y Acad Sci. 2010 Jan;1183:251-66.
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T cells in the memory stage have a higher frequency of antigen specificity and
can self-renew independent from antigen stimulation [8]. More importantly, these
persisting memory cells respond to antigen re-challenge quickly [18]. Further
analysis of memory CD8+ T cells has sub-grouped these cells into central
memory (TCM) and effector memory (TEM) cells [19-22] based on CD62L, CCR7.
TCM are CD62L+, CCR7+, and largely reside at lymph nodes, spleen and blood;
Whereas TEM localize in peripheral non-lymphoid tissues, such as lung and liver.
Viral clearance studies strongly suggest there are effector function differences
between TCM and TEM. LCMV chronical clone (that replicates rather slowly), but
not Vaccinia Virus (replicates rapidly), can be controlled by the adoptive transfer
of TCM, whereas TEM can confer protection against both types of virus [12]. In
general, it is recognized that TCM provide long-term protective immunity.

There are plenty of barriers to overcome for successful cancer immunotherapy.
Immune surveillance was not widely accepted until experimental evidence that
IFN-γ and lymphocytes collaborate to suppress the development of tumors in
mice [23, 24]. The dynamic interaction between tumors and the immune system
in cancer has recently been hypothesized to occur in three stages: elimination,
equilibrium, and escape [25]. To arrive at escape, many changes in the tumor
cells, their microenvironment, and the anti-tumor immunity, collaborate in order to
tip the balance favoring tumor outgrowth despite immune surveillance [26-29].
Tumor cells may become more resistant to apoptosis, insufficient nutrition,
hypoxia, oxidative stress and many other negative factors. Costimulatory
molecules (down), coinhibitory ligands (up) and MHC molecules (down) are
regulated on tumor cells favoring their escape. The tumor microenvironment,
including stromal cells, tumor associated immune cells, and other cell types,
produce many inhibitory factors, such as, IL-10, TGF-β, and IDO. Inhibitory
immune cells, including Tregs, Tr1 cells, immature DCs (iDCs), pDCs, and
MDSC can be found in the tumor microenvironment. Anti-tumor immune cells,
especially T cells, are subject to chronic TCR triggering by tumor antigens and
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negative tumor microenvironmental factors. Therefore, T cells become anergic or
hyporesponsive to stimulation. For example, the T cells can be driven to
differentiate to end stage effector cells without a persisting reactive memory pool.
CD8+ T cells can also abnormally differentiate into T cells with both end-stage
CTL and early effector memory features (eg. CD27+CD57+ phenotype),
producing high amount of IFN-γ and IL-13, but having low Granzyme B
expression and lacking perforin (Radvanyi L et al., unpublished observations). In
addition, CTL can become exhausted and susceptible to apoptosis after
upregulating CD57, KLRG-1, PD-1. Therefore, anti-tumor T cells have to be
liberated from the negative microenvironment in order for their efficient anti-tumor
response.

1.2 Adoptive cell therapy is effective for metastatic melanoma

Surgery and chemotherapy are currently the key therapies for melanoma;
however, the response rate remains low (about 10-12%). Throughout the years,
immunotherapy has appeared to be very promising for cancer patients. In the
case of melanoma, MART-1, gp100, TRP-2, along with other major melanoma
associated antigens have been discovered. DNA vaccines, peptides vaccines,
tumor lysate vaccines, and DC vaccines have been utilized as potential ways to
boost human immunity against tumors [30]. Although there have been some
successes in tumor control and prevention in murine tumor model studies, the
actual benefit of those modalities for cancer patients remains poor. However, in
contrast to these vaccination approaches, a strategy of combining adoptive T-cell
therapy (ACT) with high-dose IL-2 therapy has become a promising treatment
modality [31, 32].

The advantage of adoptive cell therapy relies on the ability of T cells to become
activated ex vivo without any endogenous inhibitory factors, as well as being able
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to manipulate the host environment for the transferred cells (Fig. 1-2). Tumor
infiltrating lymphocytes (TIL) cultures are initiated from freshly isolated tumor
fragments and fed continuously with high dose IL-2 in vitro. TIL can grow out
from tumor fragments, due to the presence of IL-2 in the culture. As soon as
sufficient numbers of TIL and the tumor reactivity against melanoma are
determined, cells are then processed by a rapid expansion protocol (REP). REP
uses allogenic feeder cells, OKT3 (anti-CD3 antibody, 30 ng/ml) and IL-2 (6,000
IU/ml) to stimulate and expand TIL. During two weeks of REP culture, TIL can be
expanded more than 1,000 folds. After the REP is complete, billions of TIL
(between 2.5 x 1010 to 1 x 1011) are infused into patients, together with high dose
IL-2 therapy. Adoptive cell therapy has been tested in metastatic melanoma
patients since the 1980s. An overall objective response rate (RECIST: response
evaluation criteria in solid tumors) of 34% in 86 patients was achieved with
autologous TIL plus high dose IL-2 in advanced melanoma patients [33]. Overall,
patients received two cycles of treatment in a period of two weeks, where mostly
about 1 x 1011 cells were infused in the first cycle. Analysis showed that there
was no significant difference between patient groups with or without prior IL-2
treatments, indicating autologous TIL played a critical role in the clinical response.
The state-of-the-art ACT has achieved 51% of clinical response in metastatic
melanoma patients [34]. A critical optimization of the ACT strategy was the
addition of a preparative non-myeloablative regiment (2 days of 60mg/kg
cyclophosphamide and following 5 days of 25mg/m2 fludarabine) given to
patients immediately before they received the infusion of ex vivo expanded TIL
[34]. Lymphodepleting the patient using cyclophosphamide and fludarabine was
shown

to

greatly

improve

the

clinical

efficacy.

The

benefit

of

prior

lymphodepletion is due to three possible reasons: removal of regulatory T cells,
elimination of endogenous lymphocytes acting as “homeostatic cytokine sink”,
and initiation of TLR inflammatory pathways by released pathogens [34].
Recently, total body irradiation (TBI, 2 or 12 Gy) was tested together with
lymphodepleting chemotherapy. The objective response by RECIST was
improved with increased dose of TBI, with 49% response rate with no TBI, 52%
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with 2 Gy and 72% with 12 Gy [32]. This suggests increased lymphodepletion
can enhance the clinical response of ACT. However, a random and large scale of
clinical trial should be conducted to conclude about this.

To broaden the application of ACT, PBMC have also been transduced with
retroviral MART-1 specific TCR to confer tumor reactivity. An initial clinical trial in
HLA-A2+ patients was reported in 2006. Objective regression of melanoma
lesions was observed and sustained levels of engineered T cells could be
detected up to one year post infusion [35]. As compared to non-specific ex vivo
TIL expansion, clones of TIL were also obtained and expanded for ACT. Clones
of gp100-specific T cells were generated from peptide-immunized patients, and
expanded for adoptive transfer together with IL-2 treatment [36]. Although T-cell
anti-tumor reactivity was confirmed in vitro, after infusion, clones of the T cells
rapidly disappeared and no objective clinical response was achieved by RECIST
criteria. Another study was done by Philip Greenberg [37] where MART-1- or
gp100- specific clones were generated from patients PBMC by stimulation of
dendritic cells (DC) pulsed with peptide. After establishment of the clone, T cells
were expanded ex vivo and given to patients in four infusions. Although disease
stabilization and some minor responses were induced in half of the patients
(5/10), no objective response according to RECIST was achieved. Interestingly, a
2008 case report published by the same group (Philip Greenberg) showed the
effectiveness of antigen specific T cell clones for ACT [38]. CD4+ T cell clones of
NY-ESO-1 (an antigen highly expressed on melanoma) specificity were isolated
and expanded for treatment. The patient had refractory metastatic melanoma
and failed previous extensive treatments. After ACT, the patient achieved a
durable clinical remission (26 months disease free) and other tumor antigenspecific T cells were induced as well. This encouraging case report showed how
powerful ACT is for metastatic melanoma. Many well-established murine models
have also been extensively studied [39], contributing to the understanding and
improvement of ACT. Among them, a CD8+ TCR transgenic mouse with
specificity for an MHC class I Db-restricted epitope from gp100 (called “pmel”)
-9-

has been extensively used to characterize the regulation of melanoma-specific T
cell responses in vivo [39, 40].
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Fig. 1-2. Current Adoptive T cell Therapy Protocol for Cancer (Melanoma).
Schematic display of the procedure of adoptive cell therapy is provided. TIL
isolation from freshly processed tumor fragment is shown on left up corner. Anticlockwise, in vitro culture of TIL, with high dose of IL-2, for 4-5 weeks can
generate about 50 million of cells, which is sufficient for anti-tumor activity
screening and set up of rapid expansion protocol (REP). OKT3 and allogenic
feeder cells (irradiated) are used to stimulate TIL, in presence of high dose of IL2, for two weeks. At the same period, patients are pre-conditioned for
lymphodepletion, as shown on center top. The infusion of expanded TIL (up to
100 billion cells) is followed by high dose IL-2 treatment. Typically, about half of
the patient receiving ACT can have clinical benefit, either partial response or
complete response.

-11-

Lymphodepletion

Tumor removed
by surgery
High-dose IL-2
Tumor cut up
into fragments

T-cell
infusion

Fragments put
in culture dishes
Tumor T-cells expanded
and scaled up over a
7-week period

Expanded T cells (10 to 100 billion)
pooled into one bag for infusion

-12-

1.3 Role of CD8+ CTL and CD4+ helper cells in anti-tumor responses
The requirement for CD4+ T helper cells in the priming and maintenance of CD8+
anti-tumor CTL has been well accepted. However the existence of CD4+ Treg
decreases CD8+ CTL response through cytokine deprivation, inhibitory
costimulation, negatively affecting APC and/or cell-cell contact interaction.
Retrospective analysis has shown that patients’ survival is positively correlated
with CD8+ T cell infiltration of their tumors, but not other sites. Tumor specific
CTL could be isolated from melanoma invaded lymph nodes, and exhibit ex vivo
cytotoxicity and IFN-γ secretion. In mice bearing fibrosarcomas, CD8+ CD62Leffector T cells were found to migrate to and destroy tumor masses.

However, CD8+ CTL alone do not necessarily lead to tumor rejection. In 1995, a
mice tumor model M-3 was used to dissect the functions of the subpopulations of
the immune cells in an anti-tumor effect [41]. Different subsets of cells were
mixed with M-3 tumor cells and co-administered to sub-lethally irradiated DBA/2
hosts. Splenocytes (T cells enriched) from immunized mice conferred the
protection of the recipient mice against M-3 tumor cell challenge. This protection
was antigen specific because KLN 205 carcinoma cells formed tumors despite
the presence of M-3 specific T cells. Transferring of T cell depleted splenocytes
did not mediate mice protection. Splenocytes depleted of CD4+ or CD8+ subset
conferred only partial protection from tumor growth. Ex vivo examination of T
cells used for co-administration indicated that tumor rejection was directly
mediated by T cells, not T cell-mediated stimulation of other cell types. This study
demonstrated the importance of both CD4+ and CD8+ T cells in anti-tumor
immunity. Riddell’s study [42] showed that cytotoxic T cell activity was decreased
in those patients with CMV specific CD4+ Th cell defects. This observation
suggested the critical role of CD4 T cells’ help for the persistence and function of
CD8+ CTL and therapeutic efficacy. To better understand the contribution of CD4
cells, Hu et al [43] used D5-G6 tumor cell line clone, a stable B16BL6 tumor
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transduced with GM-CSF. They showed that D5-G6 tumor primes therapeutic T
cells in MHC-II KO mice, indicating that CD4+ T cells do not play a critical role
during priming phase or acute effector phase in adoptive immunotherapy.
However, CD4+ T cells appeared to be critical for maintaining long-term CD8+
effector function and the complete eradication of residual tumors. Restifo and
colleagues have also done a series of adoptive transfer experiments using pmel
mouse T cells and B16 tumors [44]. CD4+, CD25- Th cells and CD4+, CD25+ Treg
cells were fractionated and mixed with tumor-reactive CD8+ T cells. Combination
adoptive transfers indicated that the Treg presence prevented effective
immunotherapy, while T helper cells, dependent on IL-2 production, facilitated
anti-tumor responses. Overall, the extent of the anti-tumor response varied
according to the ratios of Th to Tregs transferred in this model.

In conclusion, optimal anti-tumor responses have been found to depend on an
interplay between activated CD8+ and CD4+ T cells, especially for long-term
control of tumor growth and prevention of relapse. Thus, optimal ACT treatment
should manipulate both arms of CD4+ T cells to boost CD8+ T cell function. As
discussed later, another critical aspect in the use of T cells for ACT is the state of
differentiation of the transferred CD8+ T cells.

1.4 Differentiation state of transferred T cells affects efficacy of ACT

Strong evidence has shown that, in ACT for metastatic melanoma, clinical
efficacy is associated with tumor-specific CD8+ T cell persistence in vivo.
Retrospective analysis revealed that favorable clinical responses positively
correlated with “younger” (less differentiated) TIL cultures, shorter doubling time
(faster growers), longer telomere length, re-expression of CD27, and more
circulating TIL with the markers CD27 and CD28. These observations [32]
suggested that the state or extent of T cell differentiation likely plays a major role
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in determining the longevity of infused T cells and the success of the treatment.
Thus, an understanding of T-cell differentiation and the specific markers
associated with different states of CD8+ and CD4+ T-cell differentiation is critical
in ACT.

TCM has been shown to be superior at mediating anti-tumor responses upon
adoptive transfer [45, 46]. In pre-clinical studies, a close examination of pmel
CD8+ T cell differentiation stages in ACT of murine B16 melanoma model
showed that terminal differentiated CD8+ cells (CD27-, CD28-), possessing strong
cytolytic ability against tumor, are less effective in triggering tumor regression in
vivo [47].

Progressive stages of differentiation were achieved by multiple

stimulations (0, 1, 2, or 3 times) of pmel T cells with antigen and IL-2 to get naïve,
early effector, intermediate effector and late effector stages. Phenotypic and
microarray analysis on these T cells confirmed that the greater number of times
the T cells were stimulated, the more highly differentiated they became towards a
CD62L-, CD127-, CD27-, Granzyme(A-K)hi, IFN-γhi, KLRG1+ phenotype. T cells
with stronger cytolytic ability showed impaired anti-tumor effect in vivo. Early
effector cells subfractioned based on positive expression of CD62L identified
ideal CD8+ populations with pronounced in vivo proliferation, effective priming
from APC, and superior anti-tumor functions.

To clarify the distinct functions of the subsets of effector-memory and central
memory CD8+ T cells (TEM and TCM), Klebanoff et al used IL-2 and IL-15 as
supportive cytokines during pmel stimulation with antigens, thus generating TEM
and TCM pmel cells [46]. CD62L was again used as a marker to differentiate the
two populations. In vivo lymphoid tissue trafficking, recall response, and tumor
treatment all showed TCM produces robust anti-tumor responses. By adoptively
transferring T cells between wild type and CD62L-/- mice, it was shown that
CD62L+ T cells specifically played a functional role in anti-tumor immunity [46].
The notion that TCM is superior to TEM in ACT was also supported by a study in
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macaques done by Riddell et al [48]. CMV specific T cells were expanded by
CMV peptide pulsed monocytes from immunocompetent macaques with latent
CMV infection, and CD62L+ TCM and CD62L- TEM were sorted and cloned. Two
populations of T cells were transferred to the same host, individually but
separated at two time points by 42 days (TEM—42days—TCM) or combined but
with different markers (ΔCD19-TCM, ΔCD20-TEM). TCM CD8+ cells became the
major persisting population in these experiments. Apoptosis analysis performed
on day 1 following the adoptive transfer showed that TEM had 40% apoptotic
cells while TCM had only 5% apoptotic cells. TCM derived effector T cell
population was also able to reacquire the phenotypic and functional properties of
memory cells upon adoptive transfer, for example the reexpression of CD62L
and their ability to migrate to lymph nodes.

However, there are other studies in murine models suggesting TEM may be
more potent in mediating tumor protection. There was a study that showed
adoptive transfer of CD62L- population enhanced tumor regression [49], however
it was argued that the transferred population was not purified and therefore it was
possible that there other tumor specific T cells were involved, such as
contaminating CD62L+ T cells. Alternatively, if CD62L+ T cells were used for
treatment, prolonged tumor control could be observed, as compared to CD62L- T
cells. Recently, another study used the intradermal B16 tumor model treated with
gp100 specific pmel T cells, following tumor excision and Treg depletion [50].
The authors showed that transferred T cells maintained CD62L- predominantly
and protected mice against intradermal and i.v. secondary tumor challenges.
However, observations in this study also found a small but distinct population of
TCM residing in the mice. It is possible that the TCM provided sustained longterm protection by periodic expansion and differentiation into TEM cells. Also this
study does not challenge the notion that TCM is superior to TEM in tumor
immunity since there was not direct comparison between the two populations.
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1.5 Optimal conditions for ACT

Based on literature studies [31, 32, 51-54] and the above discussion,
development of improved ACT methods for cancer needs to consider the
following critical parameters:


Improved T cell generation techniques to increase the chance for

patients to receive ACT, either by gene (TCR) transduction in PBMC or T
cell cloning after vaccination


Alternative ex vivo expansion of T cells in order to get less

differentiated populations, using other cytokine, such as IL-15, instead of
IL-2, and other alternative expansion strategies to keep T cells from
exhaustion


Use of immunomodulating agents (anti-CTLA-4, anti-PD1, anti-4-

1BB etc.) to boost the survival and activity of transferred T cells and create
a more favorable host environment for T cells


Use of DC vaccination or TLR ligands adjuvant to enhance anti-

tumor immunity during ACT
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2. T cell costimulation

In ACT for melanoma and other solid tumors, how the infused T cells respond to
antigen reencounter in vivo is critical for their fate [55]. The cells can either get
activated in vivo, further expand, and facilitate anti-tumor CTL activity, undergo
activation-induced cell death (AICD), or be in an “anergic” state due to a lack of
costimulation. Proper co-stimulation in the context of antigenic stimulation
through the TCR can start and/or maintain robust T cell immunity against tumors.
CD27, CD28, OX40, and 4-1BB are commonly used by T cells for second
activation signals, of which, CD28 has been found to be the first and most
important mediator of T cell costimulation. There are also other negative
costimulatory molecules such as CTLA-4 and PD-1 [1]. Irregularity of these
costimulatory molecules presented in cancer facilitates the immune-escape of
tumor cells that eventually leads to loss of tumor control.

2.1 Overview of costimulatory signaling pathways in T cells: The “yinyang” of costimulation

In 1970, Bretscher and Cohn observed B cell death in the absence of a “helper”
cell signal, and introduced two signal models in lymphocyte regulation [56]. Four
years later, Lafferty and Cunningham expanded the concept further to T cells and,
importantly, suggested that signal one alone induces T cell tolerance [57].
Schwartz and colleagues [58, 59], as well as Janeway and others [60], found that
APCs can provide signal two for T cell activation. CD28 was cloned. When
ligated or cross-linked by a specific monoclonal antibody, it augmented T cell
proliferation upon suboptimal TCR triggering [61]. June and others extensively
studied the costimulatory role of CD28 in the enhancement of IL-2 secretion [62,
63]. Subsequently, CD80 (B7-1) and CD86 (B7-2) were described as CD28
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ligands. CTLA-4 was cloned on activated CD8 T cells the same year that CD28
was discovered, and B7-1 and B7-2 were also found to be a ligand for CTLA-4
[64]. Therefore in 1993, it became evident that B7-1, B7-2, CD28, and CTLA-4
pathways regulate T cell activation [65]. Then, in 1999, inducible costimulator
(ICOS) and B7-h (ICOS-ligand, B7H2, B7RP-1) was found to be another critical
pathway [66, 67]. B7-H1 had its name changed to PD-L1 upon the description of
its receptor PD-1 (programmed cell death 1), and its sibling ligands that were
also cloned with the name of PD-L2 (B7-DC). Thus, the PD-L1/2 and PD-1
pathway was established in 2001 [64, 68]. Over the past ten years, several other
novel B7 family members were discovered, including B7-H3, B7-H4 (B7-S1, B7x),
B7-S3, and BTNL2 (butyrophilin-like family member 2) [64, 69]. Most of these
new ligands currently have their corresponding receptors unidentified. The close
relationship between these B7 family members, or Ig superfamily, has facilitated
the homology research and cloning of new members [69]. Additionally,
lymphocyte activation gene 3 (LAG-3) [70], B and T lymphocytes attenuator
(BTLA) [69] are also important Ig superfamily members. Table 1-I summarized
these findings in the history.

Another important family in costimulation and coinhibition is the TNF/TNFR family
[71] that includes: CD27-CD70, 4-1BB-4-1BBL, OX40-OX40L, HVEM (Herpes
Virus Entry Mediator)-LIGHT (lymphotoxin-like, exhibits inducible expression, and
competes

with

HSV

glycoprotein

D

for

HVEM),

CD30-C30L,

GITR

(glucocorticoid-induced TNFR family related gene)-GITRL, and CD40-CD40L.
The TNF/TNFR family generally functions to sustain optimal T cell responses,
after initial T cell activation.
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Table 1-I. Key findings in the history of costimulation

Year

Scientist

1970

Bretscher;
Cohn

1974

Lafferty;
Cunningham

1989

Schwartz;
Janeway

…

June

1993
1999
2001
…

Costimulation pairs

B7-1, B7-2, and
CD28, CTLA-4
B7-h and ICOS
PD-L1/2 and PD-1
B7-H3, B7-H4, B7S3, and BTNL2
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Conceptual development on
costimulation
B cell death in the absence of a
“helper” cell signal; two signal
models in lymphocyte regulation
expanded the concept further to T
cells; signal one alone induces T
cell tolerance
APCs can provide signal two for T
cell activation
costimulatory role of CD28 in the
enhancement of IL-2 secretion

CD28. CD28 expression on human T cells is different on CD4 (over 90% and
constutively) and CD8 subset (average 50% and decreased over age). This is
contrary to mouse T cells, where CD28 is not observed to be down-regulated [72].
The expression of CD80 (absent) and CD86 (low level) on resting APC is
significantly upregulated upon activation, such as TLR ligation or cytokine
treatment. Therefore, T cell costimulation provided by CD28 is enhanced upon
danger or inflammation. The ligation of CD28 synergizes with the signaling from
the TCR to enhance proliferation and survival of activated T cells, as well as
increase cytokine production [62, 63, 73]. NFAT and AP-2 are two important
transcription factors that are activated by CD28 signaling, which effectively
reverses T cell anergy signaling. This synergistic effect was shown to lower the
activation threshold by the presence of CD28 costimulation [74, 75]. Interestingly,
Treg cells also utilize CD28 signaling to support their expansion and function [76].
Using an artificial APC system, it was shown that CD28 costimulation can
maintain peripheral Tregs with their Foxp3 expression at increased levels [76].
CD28 costimulation also activates the PI-3 kinase (PI3K)-AKT/PKB pathway
resulting in the induction of anti-apoptotic proteins of the bcl-2 family and
protection of activated T cells from TCR-mediated apoptosis [77].

According to the two signal model used to activate T cells, tumor cells cannot
deliver signal two because B7-1 and B7-2 are not found on them [64]. It is very
reasonable to pursue the ectopic expression of B7 costimulatory molecules to
render tumor cells ability to trigger antigen specific T cells, which should then
lead to the eradication of tumor in vivo. Initial mouse experiments were
conducted on melanoma and sarcoma tumors [78, 79], where the introduction
into tumor of B7-1, and later B7-2, was found to mediate CD8+ T cell-mediated
tumor rejection. The finding that APCs can cross-present tumor antigen to prime
anti-tumor T cells, however further questioned the efficacy of ectopic expression
of B7 members on tumor. The primary benefit of B7 expression on tumor cells is
most likely through the improvement of the effector phase of anti tumor response,
rather than on initial T cell priming [64, 70]. In one clinical trial with metastatic
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renal cell carcinoma where B7 vaccination was combined with systemic IL-2
administration, patients had over 70% reduction in lung or bone metastasis and
several patients had stabilized disease (SD) [80]. The extended phase II clinical
trial of this treatment had total 39 patients and the results were reported as one
CR (complete response), two PR (partial response) and 24 SD. The clinical
response is no better than immunotherapy of IL-2 alone[81]. In another trial of
non small cell lung cancer treated by B7-1-expressing tumor cell vaccine [82], 1
out of 19 patients had a partial response and 5 had stable disease. B7-1 has also
been combined with other vaccine strategies. For example, CEA was cointroduced with B7-1 by non replicating canarypox virus vector for vaccination
[83]. In adeno-carcinoma patients, CEA specific immune response was induced
and a few patients experienced stable disease. Recently, the modified ALVAC
virus B7-1 and CEA delivery system, in combination with chemotherapy was
tested on metastatic colorectal cancer [84]. However, the result was
disappointing in that the objective clinical response rate (40%) was similar with
the one where chemotherapy alone was used. TRICOM is another version of a
combinatorial vaccine, where B7-1, ICAM-1, and LFA-3 are co-expressed by a
fowlpox viral vector [85]. The combinations of CEA, MUC-1 or PSA with TRICOM
gave very encouraging preclinical results and are undergoing early clinical trials
[86, 87]. Preliminary data indicated the TRICOM vaccine is safe, and elicited
significant immune response and some clinical benefit. Overall, the strategy
utilizing B7 costimulation on tumor cells or in viral vaccine vectors to enhance
tumor immunity has significant but limited efficacy.

OX40 and 4-1BB. OX40 and 4-1BB are two interesting costimulatory receptors
for T cells in augmenting T cell responses [71]. They are expressed on activated
T cells, with respective ligands on professional APCs such as DC, B cells, and
macrophages. OX40 and 4-1BB ligation aids in boosting T cell proliferation,
cytokine production, and survival [70, 71, 88]. OX40 and 4-1BB act differently on
T cell subsets. OX40 expression is upregulated more and stimulates more
profoundly on CD4+ T cells [89]. On the contrary, 4-1BB signaling prefers CD8+ T
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cells [90, 91]. Blocking the 4-1BB pathway can impair alloantigen-specific CD8+ T
cell priming, as well as the accumulation of recipient DC within the spleen [92].
This demonstrates that 4-1BB is critical for CD8+ T cell mediated allograft
rejection. OX40 can effectively shut down Tregs. OX40 stimulation on Foxp3+
Tregs abrogates their suppressive function, and profoundly inhibits Foxp3 gene
expression [93]. More importantly, OX40 stimulation prevented the induction of
Foxp3+ Tregs (inducible Tregs) from T effector cells [94]. Furthermore, OX40L
effectively inhibits the conversion of naïve and memory CD4+ T cells into IL-10producing Tr1 cells in response to immunosuppressive drugs or immature DC
[95]. Additionally, OX40L strongly inhibits suppressive function and IL-10
production by differentiated Tr1 cells. From the above observations, it seems that
4-1BB ligation can either promote or suppress immune response depends on
different cellular context; whereas OX40 engagement mainly promotes immune
responses.

OX40 and 4-1BB seem very promising in treating cancer patients, due to their
roles in promoting T cell function. OX40 ligation promotes T cell survival and
memory generation, and more importantly, abrogates the suppressive function of
Tregs.

Forced

expression

of

OX40L

on

tumor

cells

enhances

their

immunogenicity and induces tumor rejection [96]. Another study used a different
approach where DCs were modified to increase OX40L expression. The intratumor injection of OX40L-DC effectively shrank tumors in this mice model, which
was found to be dependent on a CD8+ T cell response. Moreover, this CD8+ T
cell response is dependent on CD4+ T cells and NKT cells [97]. There have also
been reports on the use of an agonist antibody against OX40 to improve the antitumor immunity [98]. The beauty of OX40 ligation is that it affects both the
effector and regulatory sides of anti-tumor immunity for effective tumor
eradication. However, a clinical grade, humanized, monoclonal antibody for
OX40 has not been generated. 4-1BB is interesting due to its preferential effect
on activated CD8+ T cells and that it induces the expression of anti-apoptotic
genes protecting T cells from AICD. Furthermore, 4-1BB enhances CTL function
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by upregulating Granzyme B, perforin, and sometimes cytokines [71]. Reverse
signaling through 4-1BBL generates an increased production of inflammatory
mediators, enhances

cell

adhesion,

and recruits immune effectors to

inflammation sites [99]. Forced expression of 4-1BBL on tumor cells and
agonistic monoclonal antibodies for 4-1BB have been examined in murine
models [88]. Enhanced anti-tumor activity was observed in these studies, and
this was found to be critically dependent on CD8+ T cells and NK cells. Bristol
Myers Squibb (BMS) has generated a fully human anti-4-1BB monoclonal
antibody (BMS 663513) for clinical testing in cancer patients [100]. Our lab has
tested this antibody on melanoma TILs about the ability of 4-1BB to prevent T
cells from undergoing AICD caused by TCR stimulation using anti-CD3. Clear
survival advantage and enhanced CTL function were observed when anti-4-1BB
was used (Hernandez JA et al., unpublished observations). However, an
interesting phenomenon of “hyperstimulation” was also observed when higher
doses of the 4-1BB antibody were used in the presence of TCR stimulation. An
increased amount of IFN-γ secreted during stimulation and the potential induction
of IDO were hypothesized to be the culprits in this hyperstimulation. The anti-41BB antibody has also been shown to ameliorate autoimmunity in several studies
most likely through this hypercostimulation effect [101]. Therefore, developing 41BB antibody based cancer treatment requires extra caution due to above
mentioned hyperstimulation effect and its suppressive function in the tumor
immunity setting.

CD27. The other five TNF/TNFR family members on T cells or APCs that have
positive costimulatory functions are: CD27, GITR, LIGHT, CD30, and CD40 [71].
CD27 is mostly expressed on naïve CD4 and CD8 T cells, as well as NK cells,
and B cells [71]. CD27 is upregulated by TCR ligation, peaks after limited cell
division and is lost after end-stage effector cell (CTL) differentiation [102]. Its
ligand, CD70, is expressed on medullary thymic epithelium and upregulated
rapidly on activated APCs and T cells. CD27/CD70 blockade has minor affects
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on CD4 T cells, but a major impact on CD8 T cells [103]. CD8+ T cell-mediated
allo-rejection, CD8 T cell proliferation and activation, as well as expansion of
memory population, can be reduced upon CD27/CD70 blockade [103]. However,
CD70 expression on DC promotes optimal T cell priming without adjuvant help in
vivo [104]. These observations suggest that CD27 is a critical costimulatory
molecule for adaptive immunity.

PD-1 and its ligands. PD-1 is a coinhibitory receptor that was originally isolated
on activated T cells and T cells undergoing apoptosis [105]. Activated T cells, as
well as B, NKT cells, activated monocytes, express PD-1 [70, 88]. Upon ligation,
PD-1 is phosphorylated on its cytoplasmic ITIM motif, which in turn recruits
protein phosphatases (eg. SHP-2) to inhibit proximal TCR signals [106]. Knockout mice studies revealed the inhibitory function of the PD-1 pathway. PD-1
knock-out in C57BL/6 mice results in arthritis [107], while knock-out in BALB/c
mice leads to cardiomyopathy [108]. The interaction of PD-1-PD-L1 may help
prevent tissue damage caused by immune responses. PD-L2 expression,
however, is restricted to APCs [70]. Regulation of PD-L1 and PD-L2 are through
TLR4/STAT1 and IL-4Rα/STAT6, respectively, suggesting their possible distinct
functions in type I and II T-cell responses [69]. A blocking antibody against PD-L1
on DC enhanced T cell proliferation and cytokine secretion [109]. Recent studies
on chronic viral infection revealed that exhausted T cells upregulated PD-1
expression. These T cells failed to proliferate and kill target cells [110, 111].
Interestingly, applying PD-1 antibody in vivo effectively revived these exhausted
T cells [112, 113]. The studies of PD-L2 have generated some controversial data.
For example, the use of PD-L2-Ig to costimulate T cells was reported to be
inhibitory or stimulatory in different studies [70]. However, PD-L2-/- mice did give
a more definitive answer regarding its role. Antigen specific CD4+ T cells were
reduced in PD-L2 knock out mice following vaccination; and splenic injection of
colon cancer grew much rapidly and mice survival decreased in PD-L2-/condition [114]. Therefore, PD-L2 seems to have a significant stimulatory role in
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vivo, which may be explained by the existing while unidentified distinct receptor
for PD-L2.

Many types of human cancers, including melanoma, lung, colon, kidney, and
breast cancers, were reported to express PD-L1 [64, 70, 88], which may
potentially ligate PD-1 on T cells to help tumor cells escape from immune
surveillance. In renal cell cancer, higher PD-L1 expression correlates with tumor
aggressiveness and shorter survival [115, 116]. The expression of PD-L1 on both
tumor cells and lymphocytes serves as a strong indicator of bad patient outcome
associated with regional lymph node involvement, metastasis at distant sites, and
tumor necrosis. PD-L1 expression on ovarian epithelial tumor cells is negatively
correlated with the local CD8+ T cell numbers and with patient survival [117].
Experiments in vitro showed that PD-L1-transfected P815 cells are much more
resistant to cytolysis when compared to mock transfected P815 cells. Upon
inoculation in vivo, PD-L1-P815 failed to be rejected, but anti-PD-L1 antibody
could improve tumor control [118]. The naturally PD-L1 expressing myeloma cell
line J558L can be well controlled upon transferred into PD-1-/- recipient mice or
wild type mice receiving anti-PD-L1 antibody treatment [118]. On the other hand,
applying PD-1 blocking antibody greatly inhibited the metastasis of primary
tumors, in both CT26 colon cancer and B16 melanoma models [119].
Furthermore, PD-1-deficient CD8+ transgenic T cells, but not wild type or even
CTLA-4 deficient T cells, can cause tumor rejection upon adoptive transfer [120].
These studies strong suggested that blockade of the PD-1-PD-L1 coinhibitory
pathway can improve anti-tumor response both in vitro and in vivo. Based on the
abovementioned observations, two fully humanized anti-PD-1 monoclonal
antibodies have been developed, by Medarex/BMS (MDX-1106) [121] and
CureTech (CT-011) [122] respectively. PD-1 blockade using MDX-1106 during
the stimulation melanoma tumor antigen-specific T cells (MART-1) increased the
expansion of MART-1 MHC:peptide tetramer+ CTLs [123]. This correlates with
the increased IFN-γ secretion per antigen-specific cell and enhanced lysis of

-26-

MART-1+ melanoma targets. The increased CTL expansion resulted from
increased proliferation, but not decreased apoptosis [123]. Further, PD-1
blockade made these effector cells resistant to Treg inhibition [124]. This Treg
inhibition reversed the increased expression of PD-1 and PD-L1 on CTL, rescued
INF-γ and IL-2/TNF-α secretion. Therefore, the mechanisms of PD-1 blockade
mediated immune enhancement included direct augmentation of antigen-specific
and direct inhibition of the Treg suppression ability [123, 124]. Both MDX-1106
and CT-011 have been tested in phase I clinical trials and did not present serious
toxicity. Their efficacy for various tumor types has to be formally tested through
phase II clinical trials.

Additional negative B7 family members, such as B7-H3, B7-H4, B7-S3, have
been found on tumor cells or tumor associated macrophages [69, 70]. For
example, B7-H4 mRNA has been detected on various murine tumor cell lines,
including colon, prostate, breast, and lung cancers [70]. Human specimens of
ovarian and lung cancer have been found to express B7-H4 by IHC [125]. A
novel ELISA technique revealed the existence of B7-H4 in ovarian cancer
patient’s serum, ascites and tumor lysates. In fact, B7-H4 and CA-125 have been
combined to refine the sensitivity and specificity for ovarian cancer detection
[126]. B7-H4 expression on tumor cells has been associated with advanced
tumor stage. In ovarian cancer, tumor-associated macrophage (TAM) expression
of B7-H4 can be upregualted by IL-6 and IL-10, and downregulated by GM-CSF
and IL-4 [127]. These B7 family members present a novel population of
molecules that may also need to be targeted in the future for cancer
immunotherapy.

2.2 CD28 is critical for T cell reactivation
CD28 is present on the surface of T cells, and interacts with B7 receptor family
members (CD80 and CD86) on APCs to provide critical T-cell costimulation.
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Ligation of CD28 activates PI3K, AkT and Vav1 in T cells, leading to signaling
pathways that facilitate cell division and cell survival [128]. CD28 knockout mice
showed impaired anti-viral responses characterized by delayed kinetics of
primary CD8+ T cell activation [129]. Naïve T cells, as well as memory CD8+ T
cell reactivation require CD28 co-stimulation [130]. By assisting TCR signaling,
CD28 signaling in T cells functions to lower the activation threshold [74, 75].
CD28 ligation to CD80/86 on DC makes DC undergo p38 MAPK dependent IL-6
secretion, which further potentates the immune response [131]. Loss of CD28
expression is associated with chronic activation in different autoimmune diseases
(e.g., rheumatoid arthritis or RA) and T-cell senescence [132]. Accumulation of
CD28- CD4+/CD8+ T cells also increases with age in human. Functionally, CD28T cells are highly differentiated effectors, having poor IL-2 secretion and
proliferate potential, resulting in an anergic/senescent stage [132]. Studies have
also suggested that CD28- T cells can also function as regulatory (suppressor)
cells, inhibiting immune responses [133, 134].

CD28 is a cell surface receptor that is highly glycosylated and homodimeric.
From the nascent peptides of 202 amino acids, CD28 molecule has five
glycosylation sites to form a 44 kDa chain for dimerization. CD28 is in the Ig
super family due to it’s disulphide-linked immunoglobulin variable-like region on
its extracellular domain [135]. The intracellular 41 amino acid tail of CD28 is
linked to the extracellular domain through a single transmembrane region. In
order to interact with CD80 or CD86, the Met-Tyr-Pro-Pro-Pro-Tyr motif on the
CD28 extracellular domain is highly conserved in its CDR3-like region; this
conserved motif is also found on CTLA-4. The intracellular tail of CD28 does not
have any enzymatic function; instead, CD28 signals via recruiting other adaptor
proteins. The consensus sequences of the CD28 cytoplasmic domain include:
Tyr173-Met-Asn-Met, Pro178-Arg-Arg-Pro, and Pro190-Tyr-Ala-Pro [77, 135].
The Tyr173 motif renders CD28 to interact with SH2 domains on PI3K kinase
p85 subunit and adaptor protein Growth-factor-Receptor Binding protein (Grb-2)
[136, 137]. The proline rich motifs of Pro178 and Pro190 form two SH3
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consensus binding sequences, mediating CD28 signaling via other signaling
proteins [138]. Additionally, CD28 cytoplasmic domain has other tyrosine
residues (Tyr 170, 185, 188, 197), potentially mediating protein-protein
interaction [77]. For example, a CD28 mutant mouse (Y170F) has some defects
in T-cell signaling, such as the inability to activate PI3K and failure to upregulate
Bcl-xL [139]. Therefore, T cells from the mutant mice retain CD28-dependent
proliferation through IL-2 secretion, but exhibit a reduced anti-apoptosis
phenotype. In general, common PI3K-Akt-NF-κB pathways mediate CD28
downstream signaling, to support T-cell proliferation, cytokine secretion, and antiapoptosis.

CD28 engagement enhances cytokine production of T cells. IL-2 production is
augmented through MAP kinase activation [136]. An inactivating phosphatase
MAP kinase Phosphatase-6 (MKP) was discovered to interact with the CD28
cytoplasmic domain [140]. PI3K and GrB-2 are associated with the YMNM motif
of CD28 through SH2 interaction [141]. Tec, a prototypical protein kinase, can
translocate into the contact zone of T cells and APC, therefore co-localize with
CD28 and mediate cytokine secretion [142]. CD28 can also collaborate with
guanine nucleotide exchange factor VAV/SLP-76 adaptor to increase IL-2 and IL4 transcription. VAV/SLP76 interacts with the ribosome assembly chaperone
(Rac) and MEKK1 to regulate NF-κB and AP-1 pathways [143]. PKC isotypes are
also involved in CD28-regulated cytokine secretion. PKCζ is recruited into the
immune synapse and enhances NF-AT and AP-1 translocation for IL-2 secretion
[144]. PKCα is also important for IFN-γ secretion; its deficiency in T cells results
in impaired IFN-γ secretion in response to CD3/CD28 stimulation [145]. In
summary, CD28 signaling recruits PKCs, VAV/SLP76 complexes via NF-κB, and
MAP/JNK pathways to regulate cytokine secretion.

CD28 signaling also enhances T cell proliferation, which is mediated indirectly by
the enhanced cytokine secretion and directly by other signaling proteins.
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Phosphatase and tensin homolog (PTEN) is a dual-specific phosphatase. CD28
signaling directly inhibits PTEN [146], through PI3K activation. The inhibition of
PTEN results in an increase in cell proliferation. Bcl-xG, interestingly, does not
function in cell survival, but is related with cell proliferation. Bcl-xG is an essential
signaling component of CD28 ligation and its expression is restricted to activated
T cells [147]. CD28 also controls aurora B kinase, which is involved in cytokinesis
and chromosome architecture and can mediate cell proliferation [148].
Expression of aurora B in CD28-deficient T cells restores their proliferation via
mTOR, cyclinA, Rb, and CDKs. Therefore, PTEN, Bcl-xG, and aurora B are
potential mediators of CD28 signaling for cell proliferation. p27 (kip1) is a cell
cycle progression inhibitor, by inhibiting CDK2 dependent G1-S progression.
CD28 signaling induces degradation of p27[149], thereby removing the cell
division block. It has also been shown that CD28 ligation negates p18 inhibition
of CDK6/CyclinD, resulting in increased cell cycle progression [150].

CD28 ligation also promotes cell survival. Bcl-xL expression can be enhanced by
CD28 signaling through RelA and p52 recruitment of the NK-kB pathway [151]. A
novel protein, translationally controlled tumor protein (TCTP), was found to bind
to CD28 cytoplasmic domain [152, 153]. TCTP regulates cell survival by
interacting with Bcl-xL. Additionally, PI3K, Grb-2, and Gads (Grb2-related
adaptor protein 2) also regulate Bcl-xL expression. CD28 also regulates bcl-2,
bfl-1, and mcl-1 (myeloid cell leukemia sequence 1) to regulate cell survival [77].

CD28 transcriptional regulation. There are four distinct species of CD28
mRNA products that share one common phorbol-sensitive promoter region [154],
including two shorter (1.3Kb, 1.5Kb) mRNA and two longer (3.5Kb, 3.7Kb) mRNA.
Studies have demonstrated that there are two non-overlapping motifs functioning
together to initiate CD28 transcription [155, 156]. Nucleolin (Nuc) and hnRNPD0A have been identified as major components of the CD28 transcription
initiation complex. Interestingly, a key difference found between CD28+ and
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CD28- T cells is not in the overall level of these transcription factors, but in the
post-translational modification of Nuc [156]. Studies done on rheumatoid arthritis
(RA) patients showed a strong correlation between high levels of TNF-α and
CD28 loss [157]. TNF-α, together with IL-1, is major macrophage-derived
cytokines present in the RA and contributes to the vicious cytokine milieu that
results in pathological symptoms. TNF-α present in in vitro cultures of PBMC,
induces down-regulation of CD28 cell surface expression [155, 158, 159]. RA
patients receiving TNF-α blocking treatment (anti-TNF-α monoclonal antibody)
had their CD28 expression normalized and symptoms ameliorated [160]. In
contrast to TNF-α, IL-12 has been shown to upregulate CD28 expression [161].
However, there is still a lot to learn about how these cytokine signals regulate
CD28 transcription initiation and whether there is any cross-talk between these
signaling pathways.

3. Common γ chain cytokine family
3.1 Family members overview: functions on memory CD8 T cells and
their applications for cancer therapy

In the early 1990s, Noguchi and others described XSCID in humans, caused by
mutations in IL2Rγ chain [162]. It was first noticed that the patients harboring the
mutated IL2Rγ gene, lack T cell and NK cells, and their B cells are functionally
deficient. However, in knock-out mice models, deletion of IL-2 or IL-2Rα (CD25)
does not lead to abnormal T cell or NK cell development. The finding that XSCID
patients have more severe immune defects than the patients or mice lacking IL-2
or CD25, suggested the IL2Rγ is also shared by other cytokines [162]. The whole
“common γ chain cytokine family”, including IL-2, 4, 7, 9, 15, and 21, has been
completely identified and cloned. These common γ chain cytokines play critical
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roles in immune homeostasis, and are especially important in CD8 memory T-cell
formation, maintenance and reactivation [8, 163-165].

IL-2. IL-2 is the prototype T cell growth factor. CD4+ helper T cells and CD8+ T
cells can secret IL-2 in vivo [166]. Overall, IL-2 supports T cell survival and
proliferation, enhances NK cell cytolytic ability and promotes B cell Ig production
[8, 164, 165, 167, 168]. IL-2 plays important roles in generating CD4+ and CD8+
memory T cells [8, 164, 165, 167-169]. WT and IL-2-/- TCR transgenic T cells
displayed similar effects in T-cell priming; however, the overall survival is
enhanced in WT T cells, if they are transferred into cognate hosts after priming
[170]. IL-2 supports Treg and peripheral tolerance [171, 172]. High doses of IL-2
stimulation during the expansion phase can promote apoptosis of activated
lymphocytes as after TCR ligation, known as activation-induced cell death (AICD)
[173]. It has to be noted that, in a pool of T cells without TCR stimulation, IL-2 will
preferentially first activate Treg cells over other T lymphocytes due to the
constitutive expression of CD25. IL-2 deficiency is characterized by the reduced
numbers

and

decreased

function

of

Tregs,

lympho-proliferation

and

autoimmunity.

The receptor of IL-2 includes three chains: IL-2Rα (CD25), IL-2Rβ (CD122) and
IL-2Rγ (CD132, or common γ chain). On naive or basal level T cells, only
receptor γ or γ−β dimer is expressed. Upon T cell activation, CD25 is transiently
upregulated and the α−β−γ trimer structure has the highest affinity for IL-2. CD25
does not contain a cytoplasmic tail; therefore, it cannot mediate IL-2 signaling.
Treg cells (CD4+ CD25hi CD127low Foxp3+) constitutively express high levels of
CD25.

IL-2 in cancer immunotherapy. IL-2 was first described in 1965, and was first
purified and characterized by Kendall Smith and his lab in 1983 [166]. IL-2 was

-32-

the first interleukin to be cloned. Proleukin is a recombinant protein of IL-2 that is
currently being used in the clinic. IL-2 has been used as an adjuvant for vaccines
to boost CD4+ T cells in HIV patients [174-176], and as an immunotherapy agent
for cancer [177]. IL-2 was first used for renal cell carcinoma in 1992 and later for
metastatic melanoma in 1998. For the treatment of melanoma patients, IL-2 is
administrated at the dose of 720,000 IU/Kg, intra venous, every 8 hours and up
to 5 days based on the tolerance of the patient due to toxicity [177]. The toxicity
of IL-2 treatment is usually vascular leak syndrome, which causes organ edema,
hypertension and other discomfort for patients [178, 179]. This side effect was
attributed to the direct function of IL-2 on endothelial cells [180]. The clinical
response rate of IL-2 treatment remains ~14%. It is generally accepted that IL-2
predominantly expands CD8+ T cells and NK cells in order to mediate tumor
regression. Upon combination with peptide vaccination targeting a tumor antigen,
IL-2 can increase the response rate to up to 22% [177]. A Phase III trial with
more than 180 advanced metastatic melanoma patients has recently been
completed. Study arms were high dose IL-2 alone, and IL-2 plus vaccine (gp-100
peptide vaccine with IFA adjuvant). It was found that patients in the gp100
vaccine plus IL-2 arm had a significantly higher response rate, and longer
progression-free survival (2.9 months, compared to 1.6 months) [181].

A close monitoring of high-dose IL-2-treated melanoma patients has revealed
several mechanisms on how this treatment works. The basal level of STAT1 and
STAT5 phosphorylation on NK cells of certain patients is relatively high and can
be further upregulated as soon as 10 minutes upon completion of the first
infusion of IL-2 (Radvanyi L. et al., unpublished observations). In vitro studies on
a subset of Tregs, which express ICOS, suggests they are a highly suppressive
population secreting higher levels of IL-10 and exhibiting stronger suppression
upon cell-cell contact. Interestingly, it was found that the IL-2 treatment
responsive patients have a lower level of ICOS+ Tregs as compared to the nonresponding patients (Radvanyi L. et al., unpublished observations). Strategies to
reduce or eliminate ICOS+ Treg population, such as OX40 ligation [95], may be
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an ideal combination candidate for high dose IL-2 treatment, to improve the
clinical response rate.

IL-2 is extensively used in adoptive cell therapy, due to its prominent role in the
support of T cell survival and proliferation. The ex vivo expansion of tumor TIL for
adoptive infusion, uses a very high dose of IL-2 (6,000 IU/ml) [182, 183].
Additionally, T cells also get stimulation from irradiated allogenic feeder cells (in
1:200 ratio) and anti-CD3 antibody. This expansion protocol induces high rates of
T cell expansion (1,000-2,000 fold in a two week period) [182]. Upon adoptive
transfer, melanoma patients also receive the high dose IL-2 cotherapy as
cytokine support for the infused T cells.

There are some disadvantages of IL-2 use in adoptive cell therapy. IL-2 is well
known for its role in AICD and terminally-differentiating T cells [168]. The ex vivo
expanded T cells therefore may not be optimal for adoptive infusion and high
dose IL-2 may further push the cells into an exhausted state before encounter
antigen in vivo. IL-2-expanded T cells may be very susceptible to apoptosis upon
TCR ligation. IL-2-expanded T cells failed to maintain central memory phenotype
cannot sustain in vivo, and this may lead to lose of long-term tumor control. It is
not carefully studied in the ex vivo expansion of Tregs upon high dose IL-2
exposure, however, the in vivo Tregs are found to be preferentially supported by
the IL-2 cotherapy after T cell adoptive transfer. Indeed, lymphodepletion prior to
T cell infusion help increase the adoptive cell therapy clinical response rate from
34% to 51% [32]. One of the mechanisms is that Tregs were removed therefore
following adoptive transferred T cells can function much better [52, 53, 184]. But
there are still persisting and emerging of Tregs under IL-2 treatment in clinical
observation [185]. The issue of Tregs potentially limits the anti-tumor function of
IL-2.
IL-7. IL-7 is the central cytokine for T-cell development in humans and mice [164,
165, 167]. IL-7 is primarily produced by the thymus and by bone marrow stromal
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cells. IL-7 mediates the survival of naïve and memory T cells, and is required for
the development of B cells. There are two chains in the IL-7 receptor, IL-7 Rα
(CD127) and CD132. In contrast to the IL-2Rα, CD127 is highly expressed on
naïve T cells, but is quickly downregulated upon activation. This mechanism is
thought to be used for controlling IL-7 responses and the effector-to-memory
transition [165]. In the study of acute viral infection, the antigen experienced
CD8+ T cells underwent asymmetric cell division in order to generate two
daughter cells. The daughter cell proximal to the immune synapse has the
phenotypic characteristics of CTL, while the other smaller daughter cell obtains
most of the IL-7Rα mRNA and therefore the memory potential [165]. The
sustained IL-7Rα expression on the small subset of CD8 T cells thus define the
memory precursor pool [186]. IL-7Rαhi KLRG1low has been used as markers for
the memory precursor effector cell population in the peak of the anti-viral CD8 T
cell response [187-189].

Studies have been conducted by Wojciechowski and colleagues in order to
understand the mechanism of IL-7 mediated memory T cell survival [190, 191].
The regulation of Bcl-2 family members is associated with the survival benefit of
antigen specific memory T cells mediated by IL-7. It has been observed that IL-7
is critical for the T cell memory generation against viral infection. This failure of
memory is correlated with failure of upregulating Bcl-2 expression on T cells
[192]. However, IL-7Rα Y449 signaling cannot reverse this memory defect
despite its minute effect on Bcl-2 expression [193]. Therefore, it is reasoned that
there are other apoptosis related molecules that play a role in this. Bim is a major
pro-apoptotic protein that is able to permeabilize the mitochondria member,
which then initiates the apoptosis cascade. Wojciechowski et al. used Bcl-2-//Bim+/- and Bcl-2-/-/Bim-/- mice to study the role of Bim in T cell memory responses
upon antigen challenge [190]. It was shown that Bim/Bcl-2 balance is critical for
memory T cell homeostasis maintenance. More interestingly, the IL-7Rαlow shortlived memory cell population has a higher Bim/Bcl-2 ratio. In LCMV-specific T
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cells, IL-7Rαlow memory cells cannot persist and generate a memory response
[191]. Therefore, Bim and Bcl-2 are the two critical proteins targeted by IL-7
signaling to promote T cell survival.

There is another cytokine that shares the same receptor α chain (CD127) with IL7, called Thymic Stromal Lymphopoietin (TSLP) [194]. With its distinct receptor
chain TSLPR, that is highly homologous to the common γ receptor chain, TSLP
can partially restore the defective T and B cell numbers caused by the absence
of IL-7 in IL-7-/- mice, but not in IL-7Rα-/- mice [195]. This suggests that TSLP has
an overlapping role with IL-7 in lymphocytes homeostasis. Further, TSLP also
promotes the survival of CD8+ T cells [196], both in normal conditions and under
lymphopenia.

IL-7 in cancer therapy. IL-7 of human was first cloned in 1989 and has been
extensively studied for its role in T cell homeostasis for clinical application [197].
It is especially interesting that lymphopenia-induced proliferation (LIP) of T cells
is partially induced by the increased availability of IL-7 in circulation and tissue.
Naïve T cells are more responsive to the IL-7 signaling than effector T cells due
to their higher expression level of IL-7Rα, whereas Tregs are generally less
sensitive to IL-7 support given their CD127low phenotype. Therefore, IL-7 has
been investigated in the clinic for its effects on restoring of the T cell pool under
lymphopenic conditions caused by viral infection (HIV), immune-deficiency
disease, chemotherapy and other reasons. In cancer patients, IL-7 can benefit
them by several ways. Firstly, as mentioned above, chemotherapy patients
sometime undergo lymphopenia [198]. Aged patients especially have difficulty to
deal with this because of the atrophic lymph nodes and low thymic output of new
T cells. As evidenced by the data on mice models, IL-7 therapy maybe able to
help cancer patients’ immune reconstitute and potentially prolong their survival
[199, 200]. Secondly, there are reports on the topic of IL-7 augmenting
immunization responses, preferentially against weak antigens. Administration of
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IL-7 with a vaccine against minor antigen H-Y helped expansion of antigenspecific T cells specific for sub-dominant epitope and the generation of memory
cells [201]. Persistence of these memory cells lasted several months after IL-7
cessation. This suggests that IL-7 can enhance cancer vaccination weakly
immunogenic self-antigens. Thirdly, systemic administration of IL-7 to cancer
patients to enhance the anti tumor T cell survival therefore improve clinical
response, is under active clinical investigation. Two clinical trials with
recombinant human IL-7 have been reported by the NCI [202, 203]. One was a
dose escalation study with IL-7 (subcutaneous doses of 3, 10, 30, or 60 μg/kg
given every two days over two weeks). It was disappointing that no anti-tumor
response was observed in 16 patients that were treated. However, in a dose
dependent fashion, IL-7 effectively increased the levels of cycling CD8+ and
CD4+ T cells in the blood for several weeks even after IL-7 administration was
stopped. As expected, increases in Tregs were not observed. More interestingly,
T cell repertoire diversity was substantially increased [203]. Maximal tolerated
doses of IL-7 were not reached in the study and the toxicity was minimal without
evidence of vascular leak syndrome or sign of undue inflammation as with IL-2.
The second trial tested the role of IL-7 in supporting melanoma specific antigen
peptide vaccination [202]. A very similar dose schedule was used again and no
serious toxicity was observed. Although increased T cells numbers (but not
Tregs), were found after administration of IL-7, no anti-tumor response was
detected in 12 patients. However, it is premature to conclude anything, given the
dosing of IL-7 and that the vaccines given may not have been optimal. Lastly, IL7 may be very helpful in expanding T cells ex vivo for ACT. Traditionally IL-2 is
used for rapid expansion of T cells to generate ACT products for infusion.
However, it generates mostly terminally-differentiated effector T cells and
sensitizes T cells to AICD, as discussed earlier. IL-7 instead may sustain T cell
expansion ex vivo with a higher output of memory T cells. For example, in one
study CD4+ T cell specific for HBV surface antigen was extensively expanded in
two weeks in presence of IL-7 versus. IL-2 [204]. Over 4,000-fold T cell
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expansion and upregulation of NKG2D were achieved with IL-7, as compared
with IL-2 which induced less expansion and more sensitivity to apoptosis [204].

IL-15. IL-15 is a cytokine very similar to IL-2, in that 1) they share two receptor
chains: CD122 and CD132, and 2) their functional support for T cell and NK cell
proliferation and survival in vitro and in vivo [168]. IL-15 is produced mostly by
activated monocytes, epithelial cells, DC and fibroblasts. The most striking
difference between IL-15 and IL-2 is the distinct receptor alpha chain. Unlike
CD25, IL-15Rα is not expressed on target cells, instead, it binds and presents IL15 to target cells (named trans-presentation) [205]. Experiments were conducted
to transfer wild type CD8+ T cells to IL-15Rα deficient mice, or transfer IL-15Rα
deficient CD8+ T cells to wild type host. CD8 T cells lost their proliferation ability
in the first setting but not in the second [206]. These data elegantly proved the
role of IL-15 trans-presented to CD8+ T cells from other cells. Usually, transpresenting cells, such as matured DC, express both IL-15 and IL-15Rα. The two
proteins are synthesized and associated intracellularly and then transported to
the cell surface, where the complexed IL-15 can signal to neighboring cells
through their CD122/CD132 receptor complex. The trans-presentation of IL-15
has been shown to be important for the optimal activation of CD8+ T cells, as well
as the homeostasis of memory CD8+ T cells [207-210]. The high expression of
IL-2/15 Rβ chain on memory CD8+ T cells and NK cells makes them particularly
sensitive to IL-15 stimulation.

IL-15 is tightly regulated. At the mRNA level, IL-15 is constitutively expressed on
various cell types and tissues. However, detection of IL-15 protein is mostly
restricted to certain cells [211]. The translation of IL-15 has several checkpoints:
its multiple AUG elements in the 5’-UTR, which attenuate the translation; its
signal peptide sequences rendering IL-15 production very inefficient; and its Cterminal coding sequence. It is estimated that the removal of all three brakes can
boost IL-15 production 250-fold [212, 213].
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IL-15 is indispensable for NK cell development, and it has a critical role in
memory CD4+ and CD8+ T cell homeostasis [208-210]. Additionally, IL-15
enhances CTL response both in vitro and in vivo, by induction of key cytolytic
molecules, eg. IFN-γ, Granzyme B and perforin [214-216]. IL-15 also has a role in
upregulating costimulatory molecules (eg. 4-1BB) on CD8+ T cells [217, 218].

IL-15 and IL-15Rα knock-out mice lack CD8+ memory T cells [219, 220].
However mice over-expressing IL-15 exhibit an increased CD8+ memory T cell
population [221]. Further, the function of IL-15 is not only observed in the
generation of memory CD8+ T cells, but also the maintenance of the memory
pool. DC can regulate their expression of IL-15 and IL-15Rα, and CD4+ T helper
cells promote the trans-presentation of IL-15 by DC [208, 210]. Oh et al.
presented evidence that IL-15 signaling is critical for the generation of memory
CD8+ T cells [222]. They found that during the T cell priming stage, the lack of
CD4+ T cell help caused TRAIL mediated apoptosis of activated CD8+ T cells,
and very ineffective CD8+ T cell memory. Provision of IL-15 at this stage did
enhance memory CD8+ T cell generation and the following recall response. IL-15
can substitute CD4+ help, thus resulting in reduced TRAIL expression and
apoptosis of CD8+ T cells. Studies on IL-7Rαlow CD8+ memory T cells have
shown that IL-15 is vital for their survival via the PI3K-Akt pathway activation in
response to TCR restimulation [223]. Overall, IL-15 is important for CD8+ T cells
during effector-to-memory transition, as well as the memory pool maintenance by
helping cell proliferation and survival.

There are several studies addressed the differential role of IL-2 versus IL-15 in
driving T cell differentiation in some models in vivo [45, 46, 224]. It was
consistently observed that IL-15 culture can generate superior memory T cells,
and corresponding superior in vivo T cell persistence and response, than IL-2
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culture. For example, Hanspeter Pircher’s group [224] used P14 TCR transgenic
CD8+ T cells and polyclonal CD8+ T cells to compare the efficacy of IL-2 versus.
IL-15 in stimulating T cells for adoptive immunotherapy. P14 T cells cultured with
IL-15 conferred better in vivo protection against viral infection or melanoma
growth, as compared with those cultured with IL-2. This improved protection was
correlated with the longer survival of transferred T cells. Further, this observation
was shown to be true when anti-CD3/CD28 activated polyclonal CD8+ T cells
were tested for anti-viral activity in vivo.

IL-15 in cancer therapy. The history of IL-15 dates back to 1994 when it was
discovered as a new common γ chain cytokine signaling through the IL-2Rβ
chain [225]. IL-15 has similar but distinct functions compared with IL-2, making it
very attractive as a cancer treatment agent [164, 168]. In contrast to IL-2, IL-15
barely has no obvious effect on Tregs, and it does not cause effector T cell AICD,
and instead has an anti-apoptotic effect most of the time [168, 211]. It has also
been reported that IL-15 can reverse the anergy state of TIL in the tumor
microenvironment [226]. The most exciting characteristic of IL-15 is, unlike IL-2, it
is a homeostatic cytokine that promotes the survival turnover of memory CD8+
CD44+ T cells in the resting state [46, 224, 227]. These dramatic differences rely
on their different α chain receptor and the role of IL-15 trans-presentation
described earlier, as well as subtle differences in signaling downstream of their
receptors on T cells (e.g., IL-15 induces T cell proliferation through FK506binding protein 1A mediated p70 S6 kinase activation, whereas IL-2 signals
involve FK506-binding protein 1B; TRAF2 and SYK recruited to the IL-15Rα
chain) [168].

IL-15 seems emerging as a better candidate than IL-2 for cancer treatment [168].
IL-15 transgenic mice, upon syngeneic MC38 colon carcinoma cell challenge, did
not develop lung metastasis and survived much longer than wild type mice [228].
In a further study, when IL-15Rα was transduced into MC38 colon carcinoma
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cells, mice challenged with these IL-15Rα-expressing cells did not develop
tumors, whereas mice receiving unmodified tumor cells died within 40 days [228].
In ACT for melanoma in humans, prior lymphodepletion has improved the clinical
response rate. One of the mechanisms of action of lymphodepletion is inducing
an elevated level of circulating IL-15 and IL-7 in ACT patients, and this is thought
to improve TIL survival and turnover [31, 184]. How endogenous IL-15 and IL-7
affect infused TIL persistence in ACT patients is an area that needs further work.
These studies highly advocate the application of IL-15 in cancer treatment.
However, the production of recombined human IL-15 and its availability for
clinical use has been delayed due to issues with IL-15 stability in vivo. However,
recently this stability issue has been solved by manufacturing a form of IL-15
bound to the “sushi” domain of IL-15Rα, a 65 amino acid motif, mimicking IL-15
bound to IL-15Rα and its trans-presentation structure stimulating IL-15 signaling
in T cells [209]. Currently, the NCI (Bethesda, MD) is manufacturing this form of
IL-15 under GMP conditions and beginning Phase I single agent clinical trials in
metastatic cancer patients [168].

IL-21. IL-21 is most prominent for its role in promoting B cell differentiation into
plasma cells and in initiation of CD4+ T-cell polarization towards Th17 cells [229,
230]. Upon BCR signaling, IL-21 enhances naïve B cell proliferation, as well as
induces the master transcription factor Blimp-1 for IgG class switching [230, 231].
IL-21 also down-regulates IgE through the induction of Bmf (pro-apoptotic, bcl-2
modifying factor) on IgE-B cells [232] or Id2 (Inhibitor of Differentiation -2) in B
cells for class switching to IgE [233]. During Th17 cell differentiation, IL-21 is
induced by IL-6 and/or RORγt transcription factor, which in turn further amplifies
Th17 cell differentiation. In addition, the up-regulation of IL-23R induced by IL-21,
further stabilizes the Th17 lineage commitment [234-236]. Although the
production of IL-21 is mainly produced by CD4+ T cells (especially Th17 cells)
and NKT cells, IL-21R is widely expressed on T cells, B cells, NK cells, DC,
macrophages and keratinocytes [229, 230].
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IL-21 deficiency in mice does not alter lymphocyte subsets; however, the overexpression of IL-21 does increase CD8+ memory T cells with the decrease of
naïve T cells [237, 238]. In the LCMV clone 13 chronic viral infection model, IL-21
signaling on CD8+ T cells was essential for the maintenance of viral-specific
memory pool and clearance of virus [239]. Without IL-21R signaling, the viral
specific CD8+ T cells were exhausted, did not proliferate and lost effector function,
therefore failing to clear the virus [240]. In a B16 tumor model, in vitro IL-21
primed tumor-specific CD8+ T cells induced tumor regression upon adoptive
transfer, as compared to IL-2 generated T cells [241]. It was found that the T cell
programming in the presence of IL-21 is dramatically different from the one under
IL-2. For example, expression of Eomeseodermin upon antigen triggering and
the upregulation of Granzyme B and CD44 are induced by IL-2, but suppressed
by IL-21. Molecular profiling studies have shown that CD62L is upregulated on
IL-21 primed T cells [241]. In vitro stimulation of melanoma antigen-specific CD8+
T cells showed that IL-21 induced T cell expansion, as well as increased CD28
expression [242]. IL-21 cytokine administration provided better tumor control,
more persistent CD8+ memory T cells rejecting secondary tumor challenge, and
enhanced CD8+ T cell infiltration into tumors [243]. Thus, IL-21 may support
CD8+ T cells to develop into a super-memory phenotype and function. IL-21 will
be very interesting for designing novel ACT and other immunotherapies against
cancer and chronic viral infection (HIV, HBV, HCV and many others) by
programming memory T cells.

IL-21 in cancer therapy. IL-21 is the youngest member of the common γ chain
cytokine family. It has begun to be studied extensively as a tumor
immunotherapy agent [165, 229, 230]. The premise for these studies are the
previous finding described above on the positive effects of IL-21 in anti-tumor
immune responses through its maintenance of CD28 expression after CD8+ T
cell activation and synergy with IL-7 or IL-15 in boosting CD8+ T cell stimulation
[241, 242, 244-247]. There are already two published Phase I/II clinical trials on
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IL-21 in metastatic melanoma and renal cell carcinoma patients [248, 249]. The
highest dose of IL-21 given intravenously (100 μg/kg) induced some limited
toxicity, including transient lymphopenia, flu like symptoms, and other side effects,
but these were mostly mild. Both studies reported objective responses in
metastatic cancer patients (around 4% in melanoma and 20% in renal cell
carcinoma). More patients and more careful dosing of IL-21 should be done
before an accurate and optimal objective response rate can be discerned from
these clinical trials.

The role of IL-21 is tumor immunosurveillance has also been studied recently
using a number of approaches including the use of IL-21-/- and IL-21R-/- mice
[250]. Several tumor models were examined, including methylcholanthrene
(MCA)-induced sarcomas, B16 melanomas, RMAS lymphomas, MC38 colon
carcinoma, and EG7 lymphomas. NK cell activation and anti tumor effector
function was normal in the absence of IL-21 or IL-21R. Using an OVA-expressing
EG7 and MC38 tumor models, OVA-specific CD8+ T cell memory responses and
anti-tumor CTL responses mediated by CD8+ T cells were intact, in both knockout mice [250]. The only observed function of endogenous IL-21 is that it restricts
the CD8+ primary response against OVA antigen, suggesting a novel
immunosuppressive function of IL-21. To reconcile these seeming contradictionary results, it has to be emphasized that the timing and context of IL-21
signaling is important for directing the CD8+ T cell response. At priming phase,
endogenous low levels of IL-21 (in the range of pg/ml) may suppress antigen
specific CD8+ T cell expansion. However, high levels of exogenous IL-21 (in the
range of ng/ml) may sustain or boost the CD8+ T cell memory response after the
initial priming. It is possible that the suppressive function of IL-21 is through its
inhibition of DC maturation [251, 252] or its ability to induce immunosuppresive
IL-10 producing T cells [253], or both. Furthermore, the presence or absence of
antigen may also dictate the outcome of CD8+ T cell memory. These concepts
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should be rigorously tested and then used to guide the development of IL-21 in
cancer therapy.

The other aspect of IL-21 for cancer treatment is its potential for ex vivo priming
or expansion of CD8+ T cells for ACT [241, 242, 254]. The super anti tumor
response observed in B6 mice harboring B16 melanomas was achieved by
generating phenotypically and functionally distinct memory CD8+ T cell, as
compared to IL-2, for adoptive transfer. These IL-21-induced CD8+ T cells have
higher expression of CD62L and mediated stronger anti-tumor responses [241].
The synergistic effect of IL-21 and IL-15 or IL-21 and IL-7 is of special interest
due to its ability to expand better memory CD8+ T cells [244, 245, 247]. IL-21
may provide a very powerful alternative for IL-2 as a supportive cytokine added
to the REP used to expand TIL for ACT in melanoma.

3.2 Rationale for combination of different cytokines

Common γ chain cytokine family members work together, or collaborate with
other cytokines and chemokines, to regulate lymphocyte development, activation,
and homeostasis. Before antigen encounter, naïve T cells survive by IL-7
signaling. IL-R7α is also re-expressed in central memory T cells and supports
long-term survival. For optimal activation, IL-2, IL-15 and/or IL-21 can provide
proper survival and support for driving cell division. IL-2, IL-4, IL-9, and IL-21 also
polarize different T cell lineages. Each individual cytokine works in a context
dependent manner to fine tune T cell activity. The synergistic effect of
combinations of these cytokines exists naturally in vivo, and therefore is under
intensive investigation for disease treatment.
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IL-21 has been well studied for its synergy with IL-15 or IL-7 in regulating CD8+ T
cell expansion and function [244, 245, 247]. TCR-independent expansion of
lymphocytes, including NK cells, CD4+, and CD8+ T cells, were examined under
different cytokine conditions. IL-21 alone did not induce any expansion of the
three subsets of cells in during 1 week of culture. However, IL-21 and IL-15
together expanded CD8+ T cells and NK cells, not CD4+ T cells, significantly
better than IL-15 alone [247]. A relative weaker synergy was also observed when
IL-21 and IL-7 were used together [245]. IL-2 did not present any synergistic
effect in combination with IL-21. Because of the effect of IL-15 on memory CD8+
T cells, the synergy effect of IL-21 and IL-15 on this population has been tested.
Both CD62LhiCD44hi (central) and CD62LlowCD44hi (effector) memory T cells
were expanded. Furthermore, IL-21 cooperated with IL-15 to greatly increase
IFN-γ producing memory cells upon CD3 and CD28 stimulation. The expansion
of memory, as well as naïve, CD8+ T cells resulted from accelerated cell division.
To test the combination of IL-21 and IL-15 in vivo to control tumor growth, a
mouse model using B16 melanoma (gp-100 expressing) and TCR transgenic
pmel splenocytes (gp-100 specific) have been used [247]. Vaccination-primed
pmel cells effectively shrank large established tumors and prolonged mice
survival, only with exogenous IL-15 together with IL-21, but not either cytokine
alone. Only the treated mice in the IL-15 and IL-21 group survived one month,
and two out of five of them achieved complete regression with development of
vitiligo (loss of normal melanocytes) indicating the breaking of tolerance against
self melanocyte antigens. Gene array analysis on T cells under such synergistic
conditions identified higher expression of Granzyme B and c-Jun (for optimal
proliferation) in the T cells than when IL-15 or IL-21 were used alone [247]. In
another study, IL-21 and IL-15 expression plasmids were given to mice via
hydrodynamic injection, followed by challenge of the mice with lymphoma cells
intravenously [244]. Here, 80% of the IL-15- plus IL-21- treated mice achieved
complete regression, whereas the IL-15 gene treated mice were only able to
inhibit metastasis. It was found that the addition of IL-21 to IL-15 significantly
elevated the spleen CTL activity and NK killing activity of tumor inoculated mice
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[244]. The synergistic effect of IL-7 with IL-21 was also examined in another later
study [245]. CD8+ pmel T cells activated by IL-7 and IL-21 secreted increased
levels of Th1 and inflammatory cytokines, including IL-2, IFN-γ, GM-CSF, TNF-α,
IL-1β, and IL-6, but not IL-10. They also exhibited enhanced cytolytic killing ability
against B16 melanoma or hgp-10025-33 peptide-pulsed EL-4 thymoma target cells.
This improvement in CD8+ T cell expansion and function was associated with the
maintenance of IL-7Rα and CD69 expression [245]. The prolonged IL-7
responsiveness may be one of the mechanisms of IL-7 and IL-21 synergy. CD69
is an integral membrane protein and its expression after antigen stimulation
directly correlates with the functional maturation of CD8+ T cells [255]. It has also
been reported that IL-21 synergizes with IL-15 or IL-18 to efficiently up-regulate
IFN-γ production in both NK and T cells [244, 246]. Downstream signaling
analysis showed IL-21 and IL-15 synergy induced STAT1 and STAT4 activation
and their binding to the regulatory sites of the IFN-γ gene. IL-18 in synergy with
IL-21, activated the binding of NF-κB to the IFN-γ promoter region.

Since to IL-21 induces STAT3 activation, IL-6 has also been tested for its
synergy with IL-7 or IL-15 given its ability to activate STAT3 as well [256]. In a
study using p14 TCR transgenic CD8+ T cells IL-6 together with IL-7 showed
stronger synergy than IL-6 together with IL-15 in stimulating naïve CD8+ T cell
responses. Both combinations promoted the proliferation and cytolytic ability of
CD8+ T cells upon antigen stimulation. The addition of IL-6 with IL-7 or IL-15
augmented STAT5 phosphorylation and the DNA-binding activity [256].

There are many studies evaluating the combination of IL-2 with other cytokines,
in mice vaccination models and tumor models. IL-27 is mainly secreted by APC
and functions to regulate B and T cells activity. IL-2 and IL-27 induced potent
anti-neuroblastoma activity [257]. IL-27 was transfected into tumor cells (TBJ-IL27) in combination with IL-2 treatment. This strategy achieved 90% durable
complete regression, as compared with 40% regression in mice challenged with
-46-

TBJ-IL-27 receiving no IL-2 and 0% regression in of TBJ-FLAG-challenged mice
receiving IL-2. Hydrodynamic delivery of IL-27 was also tested in combination
with IL-2. Far more effective tumor control was repeatedly observed [257]. In the
combined group, a potent memory CD8+ T cells response was generated. IL-27
seemed to potentate CTL reactivity during both initial priming and the effector
phase, as well as to inhibit Foxp3+ Treg and Th17 cells.

NK cells can be very effective in killing tumor cells. IFN-γ production by NK cells
is increased by IL-4 and IL-2 [258]. This response is STAT6 dependent. IL-2 and
stem cell factor (SCF) can generate CD56bright NK cells from CD34 stem cells,
and synergistically expanded NK cells [259]. This synergistic effect was further
tested in a phase I study. MTD of IL-2 and SCF was identified and patients
tolerated the treatment well. NK cells were expanded over 2 fold on therapy [259].
However, the NK cell expansion was not better than IL-2 alone in the same dose
(650,000 IU/m2/d) [259]. Further study on the synergistic effect or IL-2 and SCF
should be carefully conducted in animal models. IL-2 has also been combined
with GM-CSF as an adjuvant for vaccination with HPV16 E7 peptide [260].
Specific immune responses, by ELISA and Cr-release assay, were enhanced by
the combination of cytokines as compared with the individual cytokines alone or
no cytokine. The combination induced higher CTL activity, better cytokine
secretion, and no expansion of Tregs. The therapeutic effect of this combination
is superior with complete regression of pre-established E7-expressing tumors.
Mice were also protected against second tumor challenge in this study by an
enhanced memory response induced by IL-2 and GM-CSF during E7 peptide
vaccination [260].
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4. Main theoretical question posed in this thesis

Treatment of metastatic melanoma with tumor reactive T cells (adoptive T cell
therapy) is a promising approach associated with a high clinical response rate.
However, optimization is required to increase the number of complete responses
and long-term survivors after this therapy. The current approach of ACT in
melanoma involves an initial phase of TIL expansion in vitro from tumor isolates
followed by a second phase of REP generating the billions of cells used as the
TIL infusion product. The expanded TIL then are infused back to patients, with IL2 cotherapy, to drive further TIL expansion in vivo and facilitate an anti tumor
response. The main question addressed in this thesis was how the currently
used REP following initial TIL expansion from melanoma tumor fragments
protocol affected the responsiveness of the CD8+ T cells to defined melanoma
antigens.

Expanded TIL come in contact with melanoma antigens in vivo after infusion into
patients and, as a result, it is critical to understand how these cells respond to
antigenic restimulation. For antigen experienced effector CD8 T cells, there are
several possible fates following antigen rechallenge (Fig. 1-3). Given proper
costimulation and cytokine stimulations, effector CD8 T cells may develop into
long-term memory cells. Increased antigen exposure or presence of inflammatory
cytokines (IL-12, TNF-α and others) can drive terminal CTL differentiation. It is
this population of differentiated CTL that confers superior tumor lysis ability due
to their highest expression of Granzyme B, perforin and IFN-γ. At the same time,
the persisting memory CD8 T cell pool can provide sustained anti tumor T cells
for long term. This fate of T cell stimulation is expected for effective tumor control
upon adoptive cell therapy. However, the other possibilities of T cell reactivation
also existing. Upon strong TCR ligation, coinhibition and/or inhibitive cytokines,
such as IL-10, TGF-β, can induce T cell anergy, apoptosis (including AICD), or
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even senescence. These types of T cell reactivation fates will lead to failure of
TIL therapy.

Since most TIL clonotypes have been shown to rapidly disappear in the blood of
patients within a few weeks after infusion, it was hypothesized that the REP
drives most CD8+ TIL to differentiate into end-stage effector cells with loss of the
effector-memory; these “post-REP” TIL then become hyporesponsive to antigen
restimulation and become more prone to apoptosis. We also hypothesized that a
subset of TIL may still be capable of survival and continued cell division after
antigen restimulation explaining why some TIL clonotypes survive long-term in
some patients. Thus, characterization of these stable responsive TIL subsets can
help guide us in improving future clinical TIL expansion methods to enrich these
specific T cell subsets for infusion.

Further more, to correct the hypothetical terminal differentiation of post-REP TIL,
certain cytokines may be tested to either modify the REP for more memory
staged TIL or revive their response against antigen rechallenge. As described
earlier, IL-7, IL-15, and IL-21 all are excellent candidates for maintain or improve
TIL’s memory phenotype and function.
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Fig. 1-3. Possible fates of TIL upon antigen rechallenge.
Infused TIL may have two types of response against tumor antigen rechallenge
in vivo. Upper group shows that proper stimulation of antigen, costimulation and
cytokine can maintain the memory phenotype and function of TIL over long term.
When further stimulated, memory TIL can differentiate into potent CTL to kill
tumor cells. This pathway can support effective tumor control, which is expected
by the ACT. However, very often, TIL will undergo apoptosis, anergy even
senescent, due to lack of proper costimulation or inhibitive cytokine environment.
This leads to the failure of tumor control in patients.
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Chapter 2

MART-1-specific melanoma tumor-infiltrating
lymphocytes maintaining CD28 expression have
improved survival and expansion capability following
antigenic re-stimulation in vitro
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Introduction
Melanoma is a type of devastating disease, however a highly immunogenic form
of cancer. The strategy of combining adoptive cell therapy (ACT) and IL-2
therapy continues to be the most effective treatment for metastatic melanoma [32,
52, 53]. One of the advantages of ACT is that the T cells that are used can be
activated ex vivo, free of endogenous inhibitory factors. ACT for metastatic
melanoma has demonstrated a rate of 51% for clinical responses in patients [32].
Moreover, transducing peripheral blood T cells with a MART-1 specific TCR has
been shown to be promising as a method to bypass the restriction of expanding
TIL from tumor fragments [35]. Historical data analysis showed that effective anti
tumor activity and durable patient remission is highly correlated with the
persistence of circulating reactive T cells that originate from the initially infused
TIL population [261, 262]. One of the key questions in ACT in this respect is how
do the infused TIL respond to tumor antigen restimulation in vivo and how can
the transferred TIL persist for long periods in context of antigenic restimulation
and treatment with IL-2.
The state of differentiation of CD8+ T cells regulates how they respond to
antigenic rechallenge, as discussed in early chapter. Retrospective analysis
revealed that favorable clinical responses during ACT for melanoma have
positively correlated with “younger” (less differentiated) TIL cultures, shorter
doubling time, longer telomere length, and more circulating TIL with expression
of CD27 and CD28 [32, 53, 261, 262]. These observations suggest that the
different states of T cell differentiation play a major role in determining the
longevity of infused T cells and the success of the treatment. T cells that are
freshly isolated from tumor fragments are mainly TEM phenotype, characterized
as being CD27+, CD28+ and CD45RA- and CD45RO+ able to secrete high levels
of IFN-γ (Liu et al, unpublished data). Large-scale expansion of isolated TIL ex
vivo is widely used in the current ACT protocols [182]. To stimulate the extensive
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expansion of TIL for therapy in the REP, high-dose IL-2 (6,000 IU/ml) and antiCD3 stimulation are used in the presence of irradiated allogenic feeder cells
(200:1 ratio to TIL). The two week expansion of TIL can induce a 1,000-2,000
fold expansion of T cells, thus, the name “rapid expansion protocol” (REP). A
critical aspect for ACT used in melanoma and other solid tumors is how the
infused T cells respond to antigen re-exposure after the T cells are infused back
into the patients. The cells can either get activated in vivo, further expand, and
facilitate anti-tumor CTL activity, or undergo activation-induced cell death (AICD),
or be “anergic” due to a lack of costimulation. Only proper costimulation in
context with antigenic stimulation through the TCR can start and/or maintain
robust T cell immunity against tumors.
It is still not clear how the ex vivo manipulation of TIL, especially CD8+ CTL,
affects their response to further antigen encounter and their overall persistence.
We hypothesized that the REP drives the TIL to further differentiate and become
hyporesponsive to melanoma antigen restimulation. The purpose of our study in
this chapter was to determine whether post-REP TIL have any changes in their
ability to respond to antigen restimulation, and if so, what would be the possible
molecular mechanism involved.
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Results
Post expansion TIL are hyporesponsive to antigen restimulation
We first investigated the ability of post-REP TIL to respond to antigen
restimulation. HLA-A2 matched allogenic DC were generated using culture
monocytes in the presence of GM-CSF and IL-4, followed by 1-2 days maturation
using ITIP cocktail (IL-1β, TNF-α, IL-6, PGE2). CD80, CD83, CD86, HLA-A2
were all highly expressed on the matured DC that were used in our experiments
for antigen presentation. MART-1 peptide was pulsed to mature DC. This DC and
MART-1 stimulation can effectively expand the MART-1 tetramer positive TIL
population, as compared to DC alone stimulation system (Figure 2-1 A). After coculture of the DC with post-REP TIL for 7 days, no extensive expansion of the
MART-1 specific TIL was observed. MART-1 specific TIL were supposed to
respond to the stimulation, however, tetramer staining did not show a robust
increase of the MART-1 specific TIL (Figure 2-1 B). Indeed, the net numbers of
MART-1 specific TIL were generally decreased in our one-week stimulation
(Figure 2-1 D). To examine whether ex vivo expansion causes the TIL to become
hyporesponsive, we tested pre rapid expansion (pre-REP) TIL using the same
settings from the DC and MART-1 stimulation mentioned above. Interestingly,
compared to the post-REP TIL, there was a significant increase in the MART-1
tetramer staining (~ 4 fold vs. ~ 0.5 fold, shown in Figure 2-1 B) and cell numbers
(data not shown). This difference in cell expansion was also demonstrated by
CFSE assay. MART-1 specific and MART-1 nonspecific pre-REP TIL actively
divided up to 8 generations, while the majority of post-REP TIL failed to
proliferate and resulted in a concentrated CFSE high population (Figure 2-1 C).
To further validate our observation, seven more TIL lines were stimulated and
examined. As shown in Figure 2-2, post-REP TIL always had decreased
expansions, which are both antigen specific and antigen non-specific (due to
presence of costimulation and IL-2 in culture). MART-1 specific TIL expansion is
about 10 folds more effective in pre-REP TIL than in post-REP TIL (Figure 2-2).
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Thus, we conclude that TIL used in the clinic for patient infusion may not be in
optimal condition as expected.
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Fig. 2-1. MART-1–specific TIL preferentially expand when restimulated with
MART-1 peptide–pulsed DC, and post-REP TIL are hyporesponsive to this form
of restimulation.
Mature DC were generated and pulsed with MART-1 peptide as described in
Materials and Methods and then used to activate TIL (1:10 ratio). The cultures
were incubated for 7 days. IL-2 (200 U/ml) was added to all cultures to maintain
viability. (A) Preferential increase in the percentage of MART-1 tetramer+ TIL
(pre-REP) by flow cytometry analysis before and after the 7-day re-stimulation
with MART-1 peptide–pulsed normal donor HLA-A2.1+ DC. Changes in MART-1
tetramer staining (B) and CFSE dilution (C) in pre-REP versus post-REP TIL
seven days after re-stimulation with MART-1 peptide–pulsed DC are shown. (D)
Total number of CD8+ MART-1 tetramer+ T cells in post-REP melanoma TIL
before and after re-stimulation with MART-1 peptide–pulsed DC.

-57-

-58-

Fig. 2-2. pre-REP TIL have better proliferate ability than post-REP TIL in
response to restimulation with antigen-pulsed DC.
Multiple lines of TIL were expanded from tumors from different patients and
restimulated at the pre-REP or post-REP stages with MART-1 peptide–pulsed
DC. The fold-increase in the bulk CD8+ TIL population (A) and the CD8+ MART-1
tetramer+ subset (B) 7 days after re-stimulation are shown for seven different TIL
lines. Each point represents a different TIL sample; the bars show the averages.
The p-value was calculated using the Student t test.
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post-REP TIL exhibited stronger cytolytic ability
Aside from cell number expansion, the acquisition of cytolytic ability is also
crucial for effective T cell responses. CD8 T cells exert their CTL function by
inflammatory cytokine secretion and direct killing, such as Granzyme B (GrB),
perforin and IFN-γ. We therefore assessed whether post-REP TIL obtained
enhanced cytolytic ability upon antigen restimulation. DC and MART-1
stimulation was used to activate the TIL for one week. After one-week stimulation,
GrB intracellular expression was quantified. And IFN-γ secretion by TIL was also
measured by cytokine intracellular staining. Upon antigenic challenge, post-REP
TIL responded with elevated levels of GrB (MFI: 1884 vs. 1062) and increased
secretion of IFN-γ (55.70% vs. 39.24%), as compared to pre-REP TIL (Figure 2-3
B). This cytolytic ability was strictly MART-1 specific since MART-1 tetramer
positive population were analyzed. In order to directly measure stimulated TIL’s
killing ability, T2 cells pulsed with MART-1 peptide were used as target cells.
After co-incubation, MART-1 specific killing of post-REP TIL was almost two folds
higher than pre-REP TIL (Figure 2-3 A). These data indicate that post-REP TIL,
upon MART-1 restimulation, can differentiate into more potent CTL, as compared
to pre-REP TIL.
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Fig. 2-3. Restimulated post-REP TIL exhibit stronger cytolytic activity than preREP TIL.
(A) CTL activity of re-stimulated pre-REP and post-REP TIL against MART-1
peptide–pulsed T2 cells using a caspase 3 cleavage CTL assay. The data shown
are normalized by dividing the percentage caspase 3-cleavage in the targets by
the percentage of CD8+MART-1 tetramer+ T cells added to the CTL assay (1:1
effector:target ratio) to calculate killing per added TIL. Statistical difference was
calculated by using Student t test. (B) Granzyme B staining of a representative
TIL line shows a higher level of staining (MFI for Granzyme B) in post-REP TIL.
Post-REP TIL synthesized more IFN-γ in response to MART-1 peptide–pulsed
DC restimulation as determined by an intracellular cytokine staining assay.
Results in panels B are representative of a minimum of three separate TIL lines
tested.
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pre-REP TIL maintained better persistence after antigen restimulation
Our in vitro stimulation system mimicked the in vivo TIL’s response to weak
tumor antigens; however, the long-term persistence of TIL has yet to be
addressed. Pre- and post- REP TIL were stimulated for one week by DC and
MART-1. After one week, the phenotypes and functional studies were addressed.
The remaining TIL in each stimulation were then cultured in presence of only IL-2,
without further antigen stimulation. We tracked the TIL for an additional three
weeks and documented their cell numbers and phenotype. Pre-REP TIL showed
increased number of persisting cells than post-REP TIL, through long-term
culture (Table 2-I). This suggested that pre-REP TIL, as compared to post-REP
TIL, have in vivo persisting advantage. Strikingly, in the TIL #2 and #3 lines, preREP TIL’s cell numbers almost tripled. However, post-REP #2 and #3 TIL lines
were unable to survive and expand over long term. These observations were all
based on MART-1 specific TIL, and we observed a similar trend in the general,
non-antigen specific TIL population. In short, pre-REP TIL had much better
persistence in long-term upon antigen restimulation.
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Table 2-I. Improved long-term survival and expansion of CD8+ MART-1
tetramer+ pre-REP TIL over post-REP TIL

TIL line

Pre-REP MART-1-specific

Post-REP MART-specific

T-cell recovery (%)a

T-cell recovery (%)

#

Day 0

Day 7

Day 28

Day 0

Day 7

Day 28

1

9.3

37

20

0.9

NDb

ND

2

7

22

34

12.4

7.6

0

3

22.1

97

89

13.8

16

5

4

12.5

31.4

24

3.2

ND

ND

5

5.5

31.2

1.7

5.0

ND

ND

TIL were stimulated with MART-1 peptide-pulsed DC on Day 0, and cultured for 7
days. Following the stimulation, there was an additional culture of 21 days with
IL-2 (200 U/ml) added every 3-4 days. The cultures were stained for CD8+MART1 tetramer+ T cells on Day 0, 7, and 28.
a

Percentage of CD8+MART-1 tetramer+ T cells recovered at the time points are

shown.
b

Not detected because cell recovery was too low after restimulation.
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post-REP TIL had a blockade in cell cycle progression and delayed apoptosis
upon antigen restimulation
In order to determine the mechanism of post-REP TIL’s hyporesponsiveness, we
looked at the proliferation and apoptosis of the post-REP TIL. Ki-67 is a molecule
marker used to detect cell cycle entry. Pre- and post- REP TIL were stimulated
by DC and MART-1 for 8 days. Post-REP TIL exhibited no expansion, while the
pre-REP TIL expanded a lot. Increased Ki-67 positive staining was observed only
on pre-REP TIL and the TIL were shown to be in G1 and S/M phase (Figure 2-4
A, B). However, post-REP TIL had a very low percentage of Ki-67 positive cells.
In contrast, when apoptosis was examined by Annexin-V and 7-AAD staining,
post-REP TIL manifested a delayed (from day 4) and increased level of
apoptosis (Figure 2-4 C, D). 7-AAD can penetrate into dead cells and bind to
nucleic acids indicating the degree of cell death. On day 7 of the stimulation,
about 60% of post expansion TIL were dead, as compared to only 5-10% of the
pre-REP TIL (Figure 2-4 C). This increased apoptosis and following cell death (7AAD positive) may reflect the lack of cell cycle progression upon stimulation early
on. Thus, our previous observations that post-REP TIL were hyporesponsive
may be accountable by the diminished proliferation and increased apoptosis of
this population upon antigen restimulation.
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Fig. 2-4. Cell cycle entry is reduced and apoptosis is increased in post-REP TIL
after restimulation with antigen.
Pre-REP and post-REP TIL including MART-1 tetramer+ CD8+ T cells were
stimulated with peptide-pulsed DC in the presence of IL-2 as already described.
The cultures were assayed for cell cycle entry and progression using staining for
Ki-67 expression and 7-AAD for DNA content after fixation and permeabilization
on day 7 of stimulation (A and B). Panel A shows flow cytometry plots of Ki-67
versus 7-AAD performed on day 7 after restimulation of two representative TIL
lines at the pre- and post-REP stages. Panel B shows the time course of
changes in Ki-67 staining in these two pre-REP or post-REP CD8+ TIL after
restimulation. (C) Post-REP CD8+MART-1 tetramer+ TIL underwent apoptosis
after re-stimulation with peptide, as measured by uptake of 7-AAD and Annexin V
staining of unfixed cells. (D) Time course of changes in 7-AAD+ and Annexin V+
CD8+MART-1 tetramer+ T cells in pre-REP and post-REP TIL after restimulation
in two TIL lines.
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CD28 expression was downregulated after TIL expansion
To delineate the molecular mechanism of the post-REP TIL hyporesponsiveness,
several possibilities were hypothesized and tested. Our hypothesis was that this
hyporesponsiveness was due to the severe telomere erosion, high inhibitory
costimulatory molecules, lack of positive costimulation, or cytokine receptor
downregulation. We first measured telomere length of pre- and post- REP TIL.
Statistically shorter telomere lengths were observed in post-REP TIL (3.7 kb vs.
5.7 kb of pre-REP TIL) (Figure 2-5). However, the telomere lengths were still
enough for at least 35 cell divisions (50-100 bp per cell division [263, 264]).
Further, OKT3 stimulation experiments supported that post-REP TIL were
capable of extensive proliferation (data not shown). Memory T cell reactivation
requires a proper combination of signals including antigen, costimulation and
cytokine milieu. Therefore, we screened a serial of molecules such as: CTLA-4,
PD-1, CD27, CD28, OX40, 4-1BB, CD25 (IL-2 Rα), CD122 (IL-2 Rβ), CD132 (IL2 Rγ) and others. We did not detect any significant differences between the preand post- REP TIL, other than CD28 expression (Figure 2-6 A). When combined
with MART-1 tetramer staining, we found that CD28 expression was significantly
downregulated during the rapid expansion (66% and 40% positive vs. 25% and
5% positive) (Figure 2-6 B). However, CD27, which is critical for memory T cell
reactivation, did not get downregulated. CD28 is a key costimulatory molecule
that quantitively lowers the T cell activation threshold and contributes to T cell
survival, proliferation and differentiation. CD28 loss could account for the lack of
responsiveness to antigen restimulation of post-REP TIL. Interestingly, we also
discovered that GrB expression was increased in post-REP TIL, which may
indicate that after expansion, TIL were more differentiated toward the effector
stage. Thus, our data suggested that post-REP TIL lost CD28 expression, which
in turn may lead to their hyporesponsiveness to antigen restimulation.
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Fig. 2-5. Telomere length is shortened after the REP.
Telomere lengths in nine independent TIL lines were determined before and after
the REP using flow cytometric FISH assay (flow-FISH). Panel A shows how the
telomere length was determined using flow-FISH analysis on a representative
TIL line. The telomere lengths were measured in gated G1-phase cells using 7AAD staining. Flow-FISH assay of K652 cells (stable telomere length) was used
to calculate the telomere lengths. Telomere length for nine independent pre-REP
versus post-REP TIL lines, with p-value, is shown in panel B. Each point
represents a different TIL sample; the heavy bar shows the average.
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Fig. 2-6. Cell-surface CD28 expression is lost after the REP.
Pre-REP and post-REP TIL from over 15 different lines were analyzed for CD27,
CD28, and CD57 cell-surface expression in the CD8+ subset using flow
cytometry. (A) Percentage of positively staining CD8+ cells for each marker is
shown for multiple matched pre- and post- REP TIL. Each point represents a
different TIL sample; the heavy bar shows the average. The p-values were
calculated by the Student t test. (B) Profound loss of cell-surface CD28
expression in the CD8+MART-1 tetramer+ TIL subset after the REP. Dot plots in
B show analysis of CD27 versus CD28 staining in the gated CD8+MART-1
tetramer+ subset in two different matched pre- and post-REP TIL lines.
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CD28 as a marker for better TIL reactivation and expansion
Recent studies have indicated that memory CD8 T cells require CD28
costimulation for reactivation and expansion. We discovered that there is a loss
of CD28 expression in post-REP TIL, however, more direct evidence is needed
to validate that CD28 loss causes TIL hyporesponsiveness. In our experiments,
two types of APCs, DC and B cells were used to stimulate TIL. The difference
between these two kinds of APCs is their CD70 expression level, with B cells
expressing CD70 almost 100% while DC expressing little, if any CD70. To our
surprise, the MART-1 stimulation presented by DC or B cells did not make
different reactivations of TIL. A closer examination of post stimulation TIL showed
their CD27 and CD28 expressions had no difference too (Figure 2-7 A). On the
other hand, post-REP TIL were stimulated and their CD28+/- subsets were
analyzed. Interestingly, we found that CD28+ TIL fragments have more CFSE
dilution than the CD28- TIL fragments. This suggested that the CD28+ TIL has
better antigen response. However, the effect was not observed when CD27 was
used to segregate the TIL populations (Figure 2-7 B). Next, a longer period of
stimulation was conducted and the CD28 expression kinetics of TIL was tracked.
A gradually dimished CD28- population was constantly observed, and at end of
stimulation, almost all of the remaining TIL were CD28+ (Figure 2-7 C).

We went on to sort the post-REP TIL into two fractions: CD4- CD28+ and CD4CD28-, using DC and MART-1 restimulation to test their responsiveness. After
one-week stimulation, CD28+ population proliferated and MART-1 specific TIL
population expanded up to 10 folds (Figure 2-7 D), however, CD28- population
did not respond well. CFSE dilution revealed that CD28+ post-REP TIL
proliferated much better than CD28- ones. This phenomenon is mirrored in part
by the pre- and post- REP TIL upon antigen restimulation. Therefore, the CD28+
population was the major subset responding to antigen restimulation, while CD28
expression was lost during ex vivo TIL expansion.
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Next, we tried blocking CD28 signaling, either through CTLA-4-Ig or by CD80
and CD86 blocking. However, in both situations, the restimulation of pre-REP TIL,
where ample CD28 expression could be found, was not affected at all (data not
shown). This observation was very surprising; however, it may suggest the
existence of a more dominant negative factor that is associated with CD28 loss
to hamper TIL reactivation.
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Fig. 2-7. Only CD28+ TIL remaining after the REP were capable of further cell
division in response to restimulation with antigen.
Post-REP TIL from an HLA-A2.1+ patient were re-stimulated with either MART-1
peptide–pulsed HLA-A2.1+ DC (CD70low/-) or MART-1 peptide–pulsed CD40Lactivated HLA-A2.1+ B cells (CD70+). (A) FACS dot plots show the change in
CD27+ versus CD28+ cells in the CD8+MART-1 tetramer+ population before and
after restimulation with the DC or B cells. (B) Differential dilution of CFSE in the
gated CD28+ versus CD28- and CD27+ versus CD27-MART-1 tetramer+ T-cell
subset 7 days after restimulation with peptide-pulsed B cells. (C) CFSE dilution
versus CD28 staining in the TIL line on panel B was tracked on days 5, 7, and 10
after restimulation, showing the preferential outgrowth of CD28+ post-REP T cells
during culture. (D) CD8+CD28+ and CD8+CD28- T cell subsets were sorted from
four independent HLA-A2.1+ MART-1–reactive patient TIL lines using FACS
followed by restimulation with MART-1 peptide–pulsed DC and measurement of
the fold-change in CD8+MART-1 tetramer+ T cell numbers after 7 days using
viable cell counting and FACS staining.
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Microarray analysis on CD28+/- TIL revealed their gene expression differences
To further understand why CD28+ TIL responded better against antigen
restimulation and long-term survival advantage, post-REP TIL were sorted into
CD8+ CD28+ and CD8+ CD28- populations for cDNA microarray analysis. The
gene expression data based on Illumina human Ref6 chip has been stored at
NCBI

GEO

database

with

Accession

(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16517).
+

#GSE16517
Differences

-

between CD28 vs. CD28 TIL were revealed by the analysis of the microarray
data. Among the 12,430 genes detected (p-value <0.01), those with more than
two folds change in expression were clustered in the heatmap (Figure 2-8 A). To
extract the biological significance of this huge amount of data, we performed the
pathway analysis. Overall, eight specific pathways were significantly different
between CD28+ and CD28- TIL, and these included genes involved in antigen
processing and presentation (28/88), such as: Killer cell Immunoglobulin-like
Receptors (KIR) pathway (47/131), TCR signaling (38/93), cell cycle (43/112),
and p53 pathway (29/68). A list of differentially expressed genes, related to T cell
memory, function, costimulation, cytokine receptors and others, were shown in
Table 2-II. We found that CD28- TIL express higher levels of cell cycle inhibitors
(eg, p15, p16, p19), and cytolytic genes (such as granzymes, TNF, perforin,
FasL). CD28- TIL expressed relatively lower level of T cell memory markers (IL7Rα and CCR7). It was surprising to observe that CD28+ TIL have a higher
expression of PD1, TP53BP2, IL-17Rβ, and IL-23A. CD28 expression level
between the sorted two populations can be found to be much separated, and this
serves as a perfect control for the whole gene expression analysis. The PD-1
flow cytometry staining has confirmed that CD28+ TIL have about two folds
higher expression on their surface. Upon cell stimulation, PD-1 expression is still
higher and may potentially inhibit the maximal proliferation of CD28+ TIL (Figure
2-8 C). In conclusion, the CD28+ TIL had distinct gene expression profiles in
antigen processing, intracellular signaling, cell cycle regulation, and apoptosis.
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Fig. 2-8. CD8+CD28+ and CD8+CD28- post-REP TIL exhibit different gene
expression profiles, as determined by cDNA microarray analysis.
Post-REP TIL from three patients were sorted for CD8+CD28- and CD8+CD28- T
cells and gene expression analyzed using cDNA microarray as described in
Materials and Methods. (A) Heatmap showing genes differentially expressed (>2fold) and having statistically significant differences in expression between CD28+
and CD28- samples (p<0.01). Onto-Tool software was used to determine
differences in gene expression in major cellular signaling or functional pathways.
(B) The signaling pathways or functions that had statistically significant
differences between CD28- and CD28+ cells (Impact Factor >20) are shown,
together with the number of genes with each difference out of the total number of
genes represented in each pathway. (C) Flow cytometry analysis of post-REP
TIL for CD28 versus PD-1 staining in gated CD8+MART-1 tetramer+ T cells after
the REP and 5 days after restimulation. The calculated percentage of PD-1+ and
PD-1- cells as a fraction of the CD28+ or CD28- subset is depicted in the dot plots.
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Table 2-II. Key immune-regulatory genes differentially and not differentially
expressed in sorted post-REP CD8+CD28+ versus CD8+CD28- melanoma TIL

BeadStudio (Illumina) was used to perform microarray analysis. Gene expression
was filtered Using a p<0.01 level of significance. A subset of relevant T cellrelated genes is shown. Real-time RT-PCR was used to validate changes in
CD28, PD-1, IL-7Rα, and KIR2DL1.

-81-

Discussion
One of the critical goals of ACT used for melanoma is to generate a large
population of optimal antigen-reactive T cells. These T cells are expected not
only to mediate immediate tumor killing after infusion, but also to persist to
mediate a longer term control or continued eradication of metastatic tumors [32,
53]. One of the major problems of the current ACT protocol is that most of the
infused TIL rapidly disappear within two weeks of infusion, and this is associated
with a transient control of tumor growth. The reason for this transient persistence
of infused TIL is still under investigation in the field. The TIL infused into
melanoma patients contact tumor antigens and a number of microenvironmental
factors, which in turn affect their effector function, cell division, and survival.
These environmental factors, in context to the state of T cell differentiation, will
ultimately regulate long-term TIL persistence. However, at present, very little is
known about how classical REP generated TIL respond to antigen restimulation
and what types of T cell phenotype are associated with TIL longer term
persistence. It was our hypothesis that the REP drives the TIL to further
differentiate and become hyporesponsive to antigen restimulation.

In our study, we addressed the above questions with an in vitro stimulation assay
to test REP expanded MART-1-specific TIL from several different melanoma
patients. TIL were isolated and expanded in a standard REP procedure [32, 52,
182]. Paradoxically, it was found that CD8+ MART-1-specific post-REP TIL were
hyporesponsive to antigen restimulation using mature peptide-pulsed DC.
Stimulated TIL failed to enter the cell cycle, with a higher apoptosis after
restimulation with antigen. In contrast, pre-REP TIL were able to enter cell cycle
and proliferated much better against MART-1 peptide restimulation. Therefore,
large-scale REP expansion potentially induces some function and phenotypic
changes in TIL, which limits their optimal responsiveness to antigenic
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restimulation. This observation helps explaining the lack of T cell persistence in
patients receiving ACT [261, 262].

One of the issues during T cell expansion is the induction of differentiation.
Extensive cell divisions are usually associated with the differentiation towards
end-stage effector cells and a decreased proliferate potential [6, 265, 266]. TIL
isolated from the tumor microenvironments are pre-activated, mainly with an
effector-memory

CD27+CD28+CD57-GB+Perf-/low

phenotype

(Liu

et

al,

unpublished data). CD27 and CD28 are critical costimulatory molecules for T cell
activation and survival [71, 128]. Viral-specific CD8+ T cells upon chronic viral
exposure have down-modulated CD27 and CD28. This phenotype is associated
with CTL terminal differentiation, exhibiting high cytotoxic and IFN-γ secretion,
but loss of proliferate potential [267]. CD57 expression is increased upon CTL
differentiation and is associated with T cells hypoproliferation. A classic case are
CMV-reactive CD8+ CD27- CD28- CD57+ GrB++ perforin+ cells that are
hypoproliferative, yet highly cytotoxic [267]. Therefore, the rapid expansion of T
cells may mimic the long-term antigen exposure; hence generate reminiscence of
such senescent viral specific T cells. We stained for CD27, CD28, and CD57, as
well as other T cell phenotypic markers during CD8+ T cell differentiation.
Interestingly, we discovered that the dramatic change on TIL upon REP is the
profound loss of CD28 expression with a small increase of CD57+ cells. However,
we did not observe a statistically significant change in CD27 expression, in both
the MART-1-specific or general CD8+ subsets. Previous results have tracked the
changes in post-REP in infused melanoma TIL. They reported a downregulation
of CD27 expression after the REP. The reason for this difference is unclear, but it
may reflect subtle differences of TIL REP protocol and feeders, as well as the
timing of IL-2 addition to the REP cultures. High levels of IL-2 can downregulate
CD27 cell surface expression on CD8+ TIL, through CD70 ligation, while lower IL2 doses leads to CD27 re-expression on the cell surface [268]. The relative low
levels of CD70 expression on feeder cells, or the insufficient CD27-CD70 contact

-83-

by T cells due to culture density, may explain the lack of CD27 downregulation in
our system.

Our sorting experiments and subsets analysis revealed that CD27 expression
does not affect TIL response to MART-1 and matured DC stimulation. Further,
the TIL’s reactivation by MART-1 peptide presented by different APCs (mature
DC and B cells) enhanced the above argument. High levels of CD70 on B cells
and low levels of CD70 on DC did not generate different TIL responses. Instead,
CD28 expression levels indicated the responsiveness of TIL upon tumor
antigenic stimulation. Thus, sustained CD28 expression on TIL delineated TIL’s
ability of continued expansion and persistence. However, post-REP TIL greatly
lost CD28 expression. This helps explain the clinical observations that very few
long-term survival TIL clonotypes could be found in patients receiving ACT [261].
This is also demonstrated by the fact that long-term persistent TIL clonotypes
tracked in ACT patients with durable remissions are associated with high CD28
expression [261]. We also found that CD28 does not play a functional role in cell
responses to antigen restimulation. This was surprising given that there are
several recent reports that suggest the role of CD28 ligation on the reactivation of
effector-memory cells [129, 130]. CD28- T cells have been reported to contain
decreased telomere lengths. This has been associated with their lack of
proliferation ability and persistence in vivo [269, 270]. Telomere erosion was
observed in our experiments, with a significant shorter length on TIL after REP.
This can be one of the explanations for post-REP TIL’s loss of proliferation upon
antigen restimulation. The fewer remaining CD28+ TIL could have kept
sufficiently long telomere to support the continuous cell division. It will be
important to study what signaling pathways and transcription factors regulate the
expression of CD28, as well as other key markers of effector-memory T-cells.
There will be a possibility to utilizing this knowledge for better maintenance of
CD28 expression. A key question is whether the maintenance of CD28
expression using different cytokines or other immune modulators will result in
cells with a less differentiated phenotype capable of better persistence and cell
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division after in vitro expansion in the REP. In other words, can we have the best
of both worlds: extensive expansion of tumor-reactive TIL together with a
favorable phenotype and continued cell division potential? The use of IL-15 or IL21, may offer an alternative approach in this context. IL-15 may be a good
alternative to IL-2 as IL-15 has been shown to maintain memory CD8+ T-cell
phenotype and facilitate the persistence of a central-memory (CD62L+ and
CCR7+) T-cell phenotype [46, 224, 227, 271].

In our study, microarray analysis on the gene expression profiles revealed some
distinct characteristics between CD8+ CD28+ vs. CD8+ CD28- TIL. This may
provide an explanation for the observed responsive and persisting CD28+ TIL
upon MART-1 antigen restimulation, as well as some potential targets to be
supported or disrupted for improved TIL’s antigenic response. Some significant
differences on TIL, with or without CD28 expression, are in the expression of
genes for key T cell functional pathways, such as cell cycle regulation, TCR
signaling, p53, apoptosis, and KIRs (Table 2-II). CD127/IL-7Rα and CCR7 are
found to be enriched in CD28+ TIL, together with the higher presence of PD-1 as
well. IL-7 signaling can promote memory CD8 T cell survival, and CCR7 has long
been described as a central memory T cell marker [8, 10]. The presence of these
markers on CD28+ TIL indicates the memory potential of CD28+ TIL. However,
PD-1 imposes a negative effect over T cell reactivation, such as inhibiting cell
proliferation and cytokine secretion [88]. Blockade of PD-1 was proved to be able
to enhance antigen specific T cell proliferation and, interestingly, reverse Treg
inhibition [123, 124]. Therefore, administration of IL-7 in combination with antiPD-1 antibody can greatly boost the CD28+ TIL response against antigen
restimulation. The clinical availability of these reagents makes this hypothesis
much more attractive [123, 124, 164]. The other highly striking difference we
observed was the high degree of KIR expression in the CD28- TIL subset. In
general, the long intracellular tail version of KIR is inhibitory for T cell function, as
opposed to the short tail’s supportive role [272]. KIR2DL family (including
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members 1 to 5) was all highly expressed in CD28- TIL, at different levels ranging
from 6-fold (KIR2DL5A) to 19-fold (KIR2DL1). Interestingly enough, NKG2D, the
activating NK receptor, was not found to be highly expressed on the CD28- TIL.
Given the functional inhibition of these KIR members, it is therefore reasoned
that the hyporesponsiveness of post-REP TIL upon MART-1 restimulation may
be the result of the ligation of these inhibitory KIRs by their ligands (MHC-B and
MHC-C). The blocking of KIR ligation, through negating the receptor or masking
their ligands should be interesting for further exploration to improve CD28- TIL
response against antigen restimulation.

In conclusion, we have discovered that TIL upon REP have a profound loss of
proliferate and survival potential upon MART-1 restimulation. The loss of CD28
expression on TIL is correlated, phenotypically as well as functionally, with the
loss of TIL responsiveness. Thus, our data provide an explanation as to why
CD28+ TIL are the dominant population with long-term persistence in patients
with more durable clinical responses. Further, our microarray data suggested
several therapeutically interventions, such as IL-7 administration, anti-PD-1 or
anti-KIR, in vivo after TIL infusion, should be able to further enhance the effect of
current ACT therapy. On the other hand, investigating methods of maintaining
CD28 expression during REP may help generate a superior memory population
of TIL, which in turn can generate optimal clinical benefits upon adoptive transfer.
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Chapter 3

IL-15 plus IL-21 during the REP maintains TIL CD28
expression and their responsiveness to antigenic
restimulation
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Introduction

Metastatic melanoma patients benefit greatly from the combination of ACT and
IL-2 therapy. The persistence of TIL after transfer has to be improved to enhance
the clinical response. We have shown that ex vivo expansion of TIL renders the
downregulation of CD28, which is associated with TIL’s hyporesponsiveness to
antigen restimulation. These observations suggest that generating less
differentiated memory phenotype TIL for patients’ adoptive transfer is critical for
the clinical response. We hypothesized that proper cytokine treatment should
help achieve this goal.

TNF-α was found to downregulate CD28 expression on T cells [157]. A higher
level of TNF-α in rheumatoid arthritis (RA) patients has consistently been
correlated with an abnormally higher frequency of CD28- T cells. It is these more
differentiated CD28- T cells who contributed to the high amount of cytokine
secretion and the uncontrolled auto-reactivity against self tissue [160]. In turn, the
applications of anti-TNF-α antibodies, for example Remicade, have proved to be
able to ameliorate patient symptoms. Interestingly enough, following the reduced
TNF-α level in patients, their CD28+ T cell proportion was gradually restored
[160]. In vitro experiments therefore were conducted and proved the direct
regulation of CD28 expression by TNF-α [157, 158, 161]. In contrast to TNF-α,
IL-12 was reported to upregulate CD28 expression on T cells [161]. Therefore,
anti-TNF-α treatment, during ex vivo expansion of TIL, would be interesting for
preserving CD28 expression.

Cytokines play important roles in T cell homeostasis and, interestingly,
sometimes interfere with the costimulatory molecules expressed on T cells. IL-15
has been shown to support optimal memory CD8 T cell reactivation, expansion
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and function development [208]. Upon IL-15 treatment, T cells upregulated 41BB expression. 4-1BB signaling promote CD8 T cell survival and cytokine
secretion, which in turn enhance the memory response [217, 273]. IL-15 also
helps to activate telomerase, therefore elongating telomere length of T cells [274].
Another interesting cytokine, a common gamma chain receptor family member,
IL-7, has also been reported to help T cell survival and elongate telomere length
[275]. IL-21 has been found to maintain CD28 expression in the presence of TCR
ligation [242]. The transgenic T cells generated with IL-21, in contrast to IL-2, had
a higher expression of c-Jun and could elicit a potent anti-tumor response upon
adoptive transfer [241]. The combinations of cytokines were also tested
regarding their functions of supporting T cell expansion. IL-21 and IL-15 or IL-21
and IL-7 have been reported as great synergistic combinations [245, 247]. Both
combinations promote stronger T cell proliferation and help develop superior T
cell function than single cytokine alone. We therefore hypothesized that different
cytokines (IL-7, IL-15) or combinations (IL-15+IL-21) can help maintain CD28
expression on T cells while expanding the cell number, either during or in shortterm post ex vivo expansion.

In a current study, we tested 1) anti-TNF-α REP (by adding Remicade); 2)
alternative cytokine for REP; and 3) alternative cytokine treatment of post-REP
TIL. This should be instructive for designing novel ACT therapy.
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Results
Large amounts of TNF-α in the REP culture can be blocked by Remicade
We discovered that there is a loss in CD28 expression in post-REP TIL, and
interestingly, TNF-α was shown to be able to downregulate CD28. To address
whether TNF-α present in the REP culture negatively affects TIL phenotypic
development, an examination of cytokine profiles of REP culture was conducted.
As a control, IL-2 was first examined. IL-2 was not detected on very early stages
of REP, day 0 and day 2 (culture supernatant sampled prior to exogenous IL-2
addition). However, since day 5, over 15 ng/ml of IL-2 could be detected and this
high level sustained at least until day9. On the other hand, TNF-α level was
elevated to about 750 pg/ml as early as day 2 of the REP. Further elevation of
TNF-α was observed at day 5 of REP, but was not sustained to day 9. The TNFα peak probably happened around day 5 of the REP.

To test the commercially available reagent Remicade for TNF-α blocking, 5 μg/ml
of this antibody was added once at day 0 of the REP. Luminex assay results
suggested Remicade could completely block the TNF-α presented in the REP, as
plotted at Figure 3-1. However, IL-2 level in the REP was not affected by
Remicade administration at all. Therefore, high levels of TNF-α present in the
REP culture and they can be blocked successfully by the use of Remicade.
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Fig. 3-1. Large amount of TNF-α is present in REP and can be blocked by
Remicade treatment.
Three TIL lines (#2002, #2085, and #2105) were used to test the cytokine profile
of REP culture, which takes 14 days. TNF-α and IL-2, as well as other cytokines
(not shown), were detected at different time points of REP (labeled on X axis of
each graph) by luminex multiple cytokine assay. As compared with regular REP
(upper panels), anti-TNF-α REP (lower panels) contains Remicade (5 μg/ml)
added once on day 0. Routine cell count and splitting, if necessary, was done in
an identical manner for all treatments.
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Anti-TNF-α REP can help CD28 maintenance but decrease cell yield dramatically
Next, we sought to address the hypothesis that removal of TNF-α in the REP can
help TIL maintain their CD28 expression. TIL were harvested and phenotyped
from anti-TNF-α REP, as well as regular REP. MART-1 reactive TIL were not
affected or enhanced by the blocking of TNF-α. As expected, a moderate
increase (about 25%) of CD28 expression on total T cells was observed with
anti-TNF-α treatment (Figure 3-2 A). However, this observation was under the
condition of Remicade addition at day 0 of the REP and at 5 μg/ml. It is possible
that refinement of the dose and timing of Remicade addition may generate
optimal CD28 maintenance on TIL during REP. Remicade titration was then
tested, and adding time was set at day 0, day 2, and day 7 of the REP. Overall
observation of Remicade addition was that the earlier it was added, the better
maintenance of CD28 expression on TIL. In addition, a lower dose (0.2 μg/ml) of
Remicade seemed to induce better CD28 maintenance. However, this increase
of CD28 expression was moderate and complete recovery of CD28 expression
was not induced (Figure 3-2 B). Blocking TNF-α greatly decreased the cell yield
of the REP. Again, the earlier and the higher dose of Remicade administration,
the lower of the cell yield (Figure 3-2 C). The poor cell yield prevented more
investigation on this anti-TNF-α strategy, since sufficient cell expansion is the
primary purpose of REP.
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Fig. 3-2. Remicade treated REP can generate TIL with CD28 maintenance.
Anti-TNF-α treatment during REP by Remicade was used to evaluate the effect
of CD28 maintenance. 5 μg/ml of Remicade was added on day 0 of REP and no
more antibodies were used for the rest of the culture period. TIL were harvested
on day 14 of the REPs; including traditional REP and anti-TNF-α REP. Flow
cytometry staining of different cell surface molecules was conducted to
phenotype different subsets and differentiation stages of TIL. CD28 expression
and MART-1 tetramer staining comparison between two kinds of REPs was
shown (A). To optimize the use of Remicade, for maintenance of CD28
expression and sufficient cell yield, the adding time and dose were tested under
different parameters, as labeled on axis (B, C). After 14 days of REP, TIL were
harvested, counted and phenotyped. CD8 T cells percentage out of total viable
cells (open bar) and CD28+ cells out of CD8 T cells were plotted for each specific
condition of REP, as compared with regular REP (B). Cell counts of final REP
products, indicating the TIL yield, were also plotted (C). Data presented are
representative for at least five different TIL lines.
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Post-REP TIL rested with different cytokines did not regain CD28 expression
Different cytokines drive distinct cellular signals and effects. During the REP,
very high dose of IL-2 may drive T cells to go through cell cycle more rapidly. It is
possible that a reduced concentration of IL-2 or alternative cytokines delivers a
resting signal for post-REP TIL, reviving the CD28 expression. In order to
investigate this possibility, IL-2, IL-7, or IL-15 were added at different doses for
one week. IL-21 was not tested since its functions were reported effective only
when in the presence of TCR ligation. IL-7 did not provide a dramatic survival
benefit for TIL. The overall apoptosis rate of post-REP TIL was fairly low (about
5% of total). IL-2 or IL-15 maintained similar cell viabilities as IL-7. It is worthy
noting that IL-15, in striking comparison to IL-2 or IL-7, did not induce a stronger
cell cycle entry. IL-15 also up-regulated perforin and GrB expression in TIL, in a
dose dependent manner. However, despite all these interesting observations,
CD28 expression level on post-REP TIL was not revived by any condition
investigated in the experiment. In the TIL line presented here, fresh post-REP TIL
has 41.35% of CD28+ on CD8+ gated population. After one week of resting with
different cytokines at different concentrations, the CD28+ remained about 40%.
These data suggested CD28 expression on post-REP TIL could not be regained
by alternative cytokine treatment.
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Fig. 3-3. IL-2, IL-7, or IL-15 does not revive CD28 expression on post-REP TIL.
Post-REP TIL were harvested on day 14 of regular REP and rested one more
week in presence or absence of different cytokines as indicated on the x-axis
label. Flow cytometry staining of different cell surface or intracellular molecules
was conducted after the rest period. The positive percentages of each molecule
among in viable CD8+ T cells was plotted, as indicated on the y-axis. Data
presented are representative for at least three different TIL lines.
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IL-15 plus IL-21added into REP in place of IL-2 helps CD28 expression on TIL
Although different cytokines did not upregulate the CD28 expression on postREP TIL, there was still the possibility that, during the REP, alternative cytokine
may drive a different pattern of TIL expansion. Given the widely reported role of
IL-15’s support on CD8 memory T cells, novel REP with IL-15 (100 ng/ml) was
tested. The TIL generated by the IL-15 REP did not change their phenotype as
compared to IL-2 REP. The general cell yield was very similar in both IL-15 and
IL-2 REP, about 1,000-fold expansion. The CD28 and CD27 expression levels on
CD8 T cells, as well as total T cells, were not improved by the presence of IL-15
(Figure 3-4 A). IL-21 (100 ng/ml) was next tested for its potential role in
preserving the memory phenotype of CD8 T cells. IL-15+IL-21 were also tested
because of the report of the synergistic combination that can promote T cell
proliferation. Interestingly, the presence of IL-21 in the REP greatly preserved
CD28 expression (~90% vs only 20% in IL-2 REP). The combination of IL-15+IL21 also helped CD28 maintenance (~70%) (Figure 3-4 B). This observation is
encouraging, since five different TIL lines all showed a dramatic increase in
CD28 expression level by the addition of IL-21 or IL-15+IL-21. However, there is
one shortcoming of the IL-21 REP despite its effect on the CD28 expression
maintenance. It is very consistent that the IL-21 REP only has about 10-20% of
cell yield of that of IL-2 REP. The IL-15+IL-21 REP actually achieved the best of
both aspects: maintaining CD28 expression, as well maintaining adequate cell
numbers (Figure 3-4 C).
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Fig. 3-4. Effects of the REP done with IL-15+ IL-21 on TIL yield and CD8+ T cell
phenotype.
TIL from the indicated patient lines were subjected to the REP using IL-2 (6,000
U/ml), IL-15 (100 ng/ml), IL-21 (100 ng/ml), or IL-15+IL-21 (both at 100 ng/ml).
Media changes with the indicated cytokines were done as for the REP with IL-2.
(A) TIL harvested after the REP using IL-2 versus IL-15 alone were analyzed for
the expression of CD28 and CD27 in the CD8+ T cell subset by FACS. The
percentage CD27+ and CD28+ CD8+ T cells isolated from six different TIL REPs
are shown with the average percentage for each parameter shown as black bar.
No statistical differences in CD27 or CD28 expression were found. (B) A
representative experiment showing the extent of CD28 expression in CD8+
MART-1 tetramer+ TIL after the REP using IL-2 alone, IL-15 alone, IL-21 alone,
or a combination of IL-15 and IL-21. Data is representative of three experiments
with similar results. (C) Five TIL lines were subjected to the REP with the
different cytokines indicated. On day 14 of the REP the percentage of CD28+
cells in the CD8+ subset was determined in comparison to the fold expansion of
the CD8+ T cells under the different conditions. In the case of IL-15 alone, only
three TIL lines were tested with “ND” denoting “not determined” for the other two
lines.
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Improved antigen-specific response in TIL after REP with IL-15 plus IL-21
The IL-15+IL-21 REP can help maintain CD28 expression on TIL; however, the
functional competence of such TIL products remains to be analyzed. We
subjected the TIL upon REPs using different cytokine cocktails to DC and MART1 restimulation. As shown in Figure 3-5 A, IL-15+IL-21 REPed TIL product
presented an improved antigen-specific response to MART-1 restimulation,
compared with those TIL from IL-2 REP or IL-15 REP. Two out of three TIL lines
undergoing MART-1 restimulation showed IL-15+IL-21 REPed TIL had a
markedly higher increase in MART-1 tetramer positive T cells one week after
restimulation. IL-21 REP preserved CD28 expression the greatest, however, in
most cases the post-REP MART-1 reactive TIL did not show an improved
antigen specific response as compared with TIL from the IL-2 REP (Figure 3-5
A). Further analysis showed that the TIL generated from IL-21 REP had a
significant higher expression levels of PD-1 than TIL generated from the REP
with IL-2, IL-15, or IL-15+IL-21 (Figure 3-5 B).
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Fig. 3-5. A combination of IL-15 and IL-21 in the REP improves the responses of
post-REP CD8+ TIL to restimulation with MART-1.
TIL from HLA-A2.1+ patients having a significant fraction of MART-1-reactive T
cells were subjected to the REP under the cytokine conditions indicated. The
isolated post-REP TIL were restimulated for 1 week with HLA-A2.1-matched DC
pulsed with MART-1 peptide, as described before. (A) The fold expansion of
CD8+ MART-1 tetramer+ T cells is shown for three different TIL lines. (B) The
levels of PD-1 expression in CD8+ TIL isolated after rapid expansion under the
cytokine conditions indicated were for analyzed by FACS. A representative
experiment from one TIL line is shown.
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Discussion

A key question that emerged from our work was how to maintain CD28
expression level on TIL during REP. This is interesting because of the ample
evidence suggesting that CD28+ TIL are indeed the responding and persisting
population against antigenic restimulation. The translational significance of such
approaches, if discovered, can be very high. The ultimate purpose of our current
study is to investigate novel methods of REP to generate a large amount of postREP TIL with a less differentiated memory phenotype, capable of better
persistence in vivo during ACT. Therefore, two possible methods were tested
here: anti-TNF-α and alternative cytokines.

TNF-α was attributed to be one of the key cytokines downregulating CD28
expression on the T cell surface [157]. This is experimentally proved and has
therapeutic implication for management of RA disease [157, 160]. Therefore, we
attempted to maintain the CD28 expression on TIL during REP by blocking TNFα. Interestingly, a high amount of TNF-α was detected during the REP from as
early as day2 of the culture. The administration of Remicade effectively blocked
the TNF-α and did not affect other key cytokines, e.g., IL-2 levels in the culture.
Further, this TNF-α blockade helped maintain CD28 on TIL (Figure 3-2).
However, the CD28 maintenance effect is not very consistent and, more
importantly, is associated with devastating damage on TIL yield. Therefore, the
strategy of anti-TNF-α REP cannot be effective for ACT protocol. On the other
hand, the blocking of TNF-α in the culture was associated with poor expansion of
TIL (Figure 3-2). We therefore hypothesized that TNF-α in the REP is critical for
optimal T cell expansion. Addressing this hypothesis is not only biologically
interesting, but also suggests a novel way of REP for ACT. For example, if TNFα is indeed critical for REP, an artificial APC (aAPC) expressing TNF-α, on top of
other costimulatory molecules, may be superior.
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Cytokines, especially the common γ chain cytokine family members, have been
documented for their distinct roles on memory CD8 T cell homeostasis [8, 163165]. IL-7, IL-15, and IL-21 are very interesting candidates for preserving CD28
expression on TIL, as compared with IL-2. IL-2 used in the traditional REP has
been shown to drive effector T cells differentiation much more rapidly, but the
expanded T cells are more susceptible to AICD.

We tested the possibility of these different cytokines to revive the CD28
expression of post-REP TIL. IL-7 is best known for its survival support in naïve
and memory T cells. IL-15 could be a better alternative to IL-2, as IL-15 has been
proven to maintain CD8 T cells of a central-memory (CD62L+ CCR7+) phenotype
[46, 224, 227, 271]. Additionally, it was reported that IL-15 can activate
telomerase and prevent telomere length from shortening on T cells [274]. Rapid
expanded TIL lose their CD28 expression, and short-term post-REP TIL with IL-7
or IL-15 as compared with IL-2, could not help restore CD28 expression (Figure
3-3). This observation indirectly proves that slowing down of rapid expansion
could not maintain CD28, or less likely, once CD28 expression is lost, it cannot
be regained. IL-15, in contrast to IL-2 or IL-7, greatly improved TIL cell cycle
entrance in the absence of TCR stimulation, as indicated by the expression of Ki67 (Figure 3-3). This may suggest that IL-15 should be considered for optimal TIL
culture in clinical. IL-15 cultured TIL presented increased expression levels of
Granzyme B and perforin, two key cytolytic molecules for CTL function (Figure 33). Collectively, the lost of CD28 cannot be reverted by different cytokine
treatment on post-REP TIL; however, IL-15 may be superior in support post-REP
TIL expansion and function.

IL-21 has been reported to exhibit an opposing role to IL-2 when driving CTL
differentiation upon antigen contact [241, 242]. IL-21 has also been found to able
to maintain CD28 expression on PBMC CD8 T cells after multiple rounds of
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MART-1 peptide stimulation [242]. We then tested the effects of IL-15 or IL-21 vs.
IL-2 in the REP. IL-15 REP generated almost the same yield and phenotype of
the TIL as the IL-2 REP. Although IL-21 was remarkably better at maintaining a
high CD28 expression, it was very poor at post-REP TIL cell yields. Therefore,
IL-21 REP is not optimal for the clinic since high number of post-REP TIL are
required for infusion. Surprisingly, the combination of IL-15 and IL-21 in the REP
provided both a significant maintenance of CD28+ expression on the TIL and a
high level of TIL expansion. Therefore, IL-15 and IL-21 generated a synergistic
effect on TIL during the REP. This is consistent with previous reports [247]. By
ligating their different surface receptors, IL-15 signaling drives extensive cell
division and has some effects on maintaining the memory CD8 population; IL-21
signaling can strongly preserve CD28 expression although IL-21 is a poor
promoter of TIL proliferation. In addition, different post-REP TIL were tested on
their functions in responding to MART-1 restimulation. In most cases, IL-21 REP
generated TIL did not show an improved response, despite containing the
highest proportion of CD28+ CD8+ TIL. The IL-15+IL-21 REP generated TIL
showed the best reactivation upon MART-1 antigenic restimulation. A possibility
is that the TIL derived from IL-21 REP express significantly higher levels of PD-1
(Figure 3-5). This may have an inhibitive effect on the activation and proliferation
of the TIL, since the APCs used for stimulation have higher expressions of B7H1
and B7DC.

In conclusion, we have evaluated two possibilities to improve the REP protocol
used in the clinic to generate TIL infusion products. The ideal protocol should be
able to maintain CD28 expression on TIL in order for an optimal TIL response
upon antigenic encounter, as well as to achieve an optimal cell yield. Although
TNF-α can downregulate CD28, the blockade of this cytokine during REP
surprisingly decreases the cell expansion dramatically. Post-REP TIL cannot be
revived of their CD28 expression with the different cytokines tested in the shortterm resting culture. Finally, the synergistic effect of IL-15 and IL-21 can generate

-107-

phenoptypically less differentiated post-REP TIL and a good cell expansion. Our
results suggested that IL-15+IL-21 may be superior to IL-2 in the REP for optimal
ACT products.
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Chapter 4

IL-15 is superior to IL-2 in supporting antigen-specific expansion
and maintenance of T cell memory in melanoma CD8+ tumorinfiltrating lymphocytes
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Introduction

The success of adoptive cell therapy (ACT) using expanded TIL for metastatic
melanoma relies on the ability of tumor antigen-specific T cells to persist and
maintain their anti tumor effector function over long term. The advantage of ACT
is that the T cells can be activated ex vivo, free of endogenous inhibitory factors,
and also, the host environment can be manipulated to accommodate these
transferred cells [32, 34, 38, 52, 53]. Several retrospective studies have indicated
that strong anti-tumor activity and durable remission of metastatic melanoma is
highly correlated with the presence of persistent, circulating reactive T cells upon
infusion [261]. TIL with a memory phenotype (CD27+, CD28+) have been found to
persist in responding patients, while they were present in low numbers or were
absent from non-responding patients [276]. Thus, a key issue in improving ACT
is discovering how to enhance the infused T cells’ response to tumor antigen restimulation in vivo and how to effectively generate the anti-tumor memory
response [32, 261, 262]. Currently IL-2 cotherapy is used for ACT. We
hypothesized that alternative cytokine treatment maybe needed to improve the
TIL function.

Current research is examining more closely the culture conditions needed to
generate TIL with improved persistence following adoptive transfer. One strategy
for improving persistence currently being investigated is the cotransfer of
cytokines, such as IL-2 and IL-15. IL-2 and IL-15 share a common receptor
gamma chain (CD132) [8, 164, 165, 277]. When T cells are activated, CD122
and CD25 are upregulated and form a heterotrimeric high-affinity receptor for IL2 (IL-2Rαβγ). Conversely, IL-15 binds to its high-affinity receptor, IL-15Rα, and is
transpresented to neighboring cells [211, 278]. Biophysical analysis has revealed
that contact between IL-15 and IL-15Rα involves a large network of ionic
interactions, whereas IL-2 and IL-2Rα contact is dominated by hydrophobic
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interactions [211, 271]. IL-2 is critical for T cell expansion and survival; however,
the responders include both CD8+ effector CTLs and CD4+ regulatory T cells. IL15 plays a important role in the long-term expansion and homeostatic
proliferation of CD8+ memory T cells, both in vitro and in vivo [46, 208, 227].
Several mouse studies, conducted to compare the supportive functions of IL-15
and IL-2, have concordantly suggested that IL-15 can generate central memory T
cells (CD62L+). IL-15 generated TCM can mediate a better immune response
against tumor in vivo [224, 226]. Many studies have evaluate the effect of IL-15
from the perspective of cancer immunology (gp-100-specific pmel model) [46, 47]
and viral immunity (LCMV-specific p14 model) [48], as well as from an analysis of
polyclonal CD8+ T cells [227].

Recently it was proposed that dendritic cell (DC) vaccination should be combined
with ACT and IL-2 therapy. This suggestion was based on evidence from a
mouse study showing that the anti tumor effect of adoptive transferred T cells
was enhanced by DC vaccination, in that DC vaccination after ACT greatly
increased T cell persistence in vivo [279]. Thus, a clinical trial of the IL-2-ACT-DC
strategy is now ongoing at M. D. Anderson Cancer Center. Given the distinct
transpresentation mode, DC may be used to present IL-15 in vivo.

However, to our knowledge, no one has examined whether cotherapy with an
alternative cytokine, in particular IL-15, would improve this treatment. We
hypothesized that IL-15 has better supportive effects for TIL, than IL-2. We
developed an antigen-specific stimulation system (using mature DCs pulse with
MART-1 peptide) to track TIL responses in an in vitro system that closely
resembles in vivo physiological conditions. The results of the present study can
be used to guide the immediate clinical evaluation of IL-15 in place of IL-2 with
ACT in patients with metastatic melanoma.

-111-

Results
IL-15 drives stronger CD8 expansion and GrB expression upon T cell stimulation
We first investigated the ability of TIL to respond to antigen restimulation in the
presence of IL-2 or IL-15. To specifically stimulate and track antigen-specific TIL,
mature DC were used to present the MART-1 peptide. Mature DC were
examined for their surface expression of CD80 and CD86, as well as expression
of IL-15Rα (Figure 4-1 A). DC used in our experiment were shown to be able to
effectively transpresent IL-15 to T cells. Without cytokine support, DC pulsedpeptide stimulation was not sufficient to activate T cells to proliferate. After one
week of stimulation, few live TIL were obtained. IL-2 and IL-15 were titrated to
determine the optimal dose of each cytokine in supporting TIL restimulation (data
not shown). Consistent with other reports, we found that 200 IU/ml of IL-2 and 10
ng/ml of IL-15 were able to support T cell stimulation, without any excessive
effects, such as AICD.

To examine whether IL-2 and IL-15 differed in their ability to support TIL
restimulation, we subjected MART-1+ TIL lines to DC stimulation. Expansion of
the TIL population was observed after coculture with DC and MART-1
supplemented by exogenous cytokines. At day 7 of the stimulation, TIL were
harvested and stained. Flow cytometric analysis of cell subsets, as defined by
their unique differentiation and activation markers, was then conducted. In
several TIL lines derived from different patients, IL-15 stimulation always
generated more CD8+ TIL than IL-2 (Figure 4-1 B). This is consistent with
previous reports, and is potentially very important to ACT for melanoma because
CD8+ TIL are the primary population that confer anti tumor responses in
melanoma patients. The number of infused CD8+ T cell positively correlates with
clinical efficacy. Intracellular staining of GrB, a cytolytic molecule that digests
various substrates to facilitate cell killing, also differed between the IL-2 and IL-15
stimulations (Figure 4-1 C). IL-15 generated about 1.5 fold more GrB positive TIL
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than IL-2 (45% vs. 30%). These data suggest that one week of IL-15 stimulation
drove a greater CD8+ TIL response and generated more GrB in activated cells.
To test whether this enhanced GrB expression was due to direct cytokine support
or indirectly through DC, we exposed TIL to cytokine alone in the absence of
antigen stimulation for one week. Co-staining of GrB and perforin showed that IL15 upregulated both cytolytic molecules in a dose-dependent manner, while IL-2
barely changed their expression levels (Figure 4-1 D). This finding suggests that
IL-15 alone was sufficient to enhance the cytolytic ability of TIL, independent of
TCR ligation. However, we could not exclude the possibility that the effect was an
indirect one and attributable to IL-15’s superior ability to stimulate DC.
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Fig. 4-1. IL-15 stimulation preferentially expands the population of CD8+ CTLs
and increases GrB expression.
Mature myeloid DC ere generated by culture with GM-CSF, IL-4 and ITIP
maturation cocktail. Surface expression of IL-15Rα, as well as the co-stimulatory
molecule CD80, CD86 and other antigens, was examined by flow cytometry
staining (A). TIL derived from melanoma patients were stimulated by mature DC
pulse-treated with MART-1 peptide for 1 week, in the presence of either IL-2 (200
IU/ml) or IL-15 (10 ng/ml). After the TIL were stimulated, flow staining was
conducted to monitor TIL activation, differentiation, and cytolytic ability, along
with tetramer staining. CD8 and GrB differed between the IL-2 and IL-15
stimulations. Summarized data from several TIL lines have been plotted in (C),
where the heavy black bar indicates the mean percentage. Cytokine alone (as
indicated) without antigen stimulation was used to support TIL for 1 week. GrB
and perforin staining gated on MART-1+ TIL was shown, as compared to isotype
staining (D).
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IL-15-stimulated TIL portrayed enhanced antigen-specific killing ability
The level of GrB staining does not directly correlate with TIL cytolytic activity.
This may be due to weaker recognition of the target or a lack of cooperation from
other cytolytic molecules, such as perforin. To help resolve this issue, we tested
how TIL exert their CTL function by examining inflammatory cytokine secretion
and direct killing of T2 target cells pulsed with MART-1. IL-15-stimulated TIL
were hypothesized to possess enhanced cytolytic ability upon antigen
restimulation. TIL were challenged with the MART-1 peptide pulsed T2 target
cells for 18 hours, after which IFN-γ secretion by TIL was measured by ELISA of
the supernatant. Indeed, we found that IL-15-stimulated TIL secreted more IFN-γ
than IL-2-stimulated cells. Combined with the MART-1 tetramer staining, per cell
antigen-specific IFN-γ secretion was calculated and plotted (Figure 4-2 A). IL-15stimulated TIL presented at least 5 times higher levels of IFN-γ upon target
contact. To directly measure the TIL killing ability, we used a highly sensitive flow
cytometry-based CTL assay measuring the cleavage of caspase 3 in target cells
[280]. T2 cells pulsed with MART-1 peptide were the targets, and were mixed
with stimulated TIL at different effector-to-target ratios (Figure 4-2 B). For a fair
comparison, MART-1 staining was also taken into consideration so that per cell
MART-1-specific killing could be calculated. As shown in Figure 4-2 C, IL-15stimulated TIL generally have two to three folds better killing ability. These data
indicate that IL-15-stimulated TIL, in response to MART-1 restimulation, can
differentiate into potent CTLs compared with those stimulated by IL-2.
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Fig. 4-2. TIL gained enhanced cytolytic ability after IL-15 stimulation.
After one week of stimulation, TIL were harvested, and their direct target-killing
effect was tested. T2 cells pulsed with MART-1 peptide or HIV peptide as control
were mixed with TIL at different effector-to-target ratios, as indicated. IFN-γ was
measured by ELISA on the culture supernatant, which was collected at 18 hours
after the CTL reaction was initiated. Net IFN-γ per MART-1+ TIL was calculated
considering the MART-1 tetramer-positive T cell percentage in the TIL (A). A flow
cytometry-based sensitive CTL assay to measure cleavage of caspase 3 (B) was
also used to test post-stimulation TIL function. In 10 TIL lines, the cytotoxicity of
MART-1+ TIL was calculated similar to the IFN-γ secretion ability described
above, and the results are plotted in (C).
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Long-term persistence of memory T cells is maintained better by IL-15 than IL-2
Our in vitro stimulation mimicked the TIL in vivo response to weak tumor
antigens; however, long-term TIL persistence had yet to be addressed. Either IL2 or IL-15 was added to DC and MART-1 restimulation for one week. We
determined the MART-1 specific TIL expansion at end of stimulation, by cell
count and MART-1 tetramer staining. After the phenotyping and functional
studies, the remaining TIL in each case were returned to culture and provided
with only cytokine support, without further antigen stimulation. We tracked the TIL
for three additional weeks and documented their cell numbers and phenotype. As
seen in Figure 4-3, short-term (one-week) stimulation of the TIL yielded a strong
antigen-specific cell expansion. TIL expanded on average 8.2-fold in the IL-2
setting, and 13-fold in the IL-15 setting. Conversely, in long-term (28 day)
expansions, the populations of TIL expanded only 1.9-fold in response to IL-2 but
4.8-fold in response to IL-15. This result revealed IL-15’s potential advantage for
in vivo stimulation and expansion of the TIL population. In multiple TIL lines, IL15 had a statistically significant benefit only for long-term expansion.

Phenotyping of tetramer and memory T cell marker staining also revealed the
preferential maintenance of memory antigen-specific TIL by IL-15. For example,
in one TIL line, after 4 weeks, IL-2 support maintained only 3.26% of MART-1+
TIL, whereas IL-15 support maintained 36.77% (Figure 4-4 A). Over the long
term, IL-15 also expanded more CD8+ TIL than IL-2 (87% vs. 74%). By
comparing the MART-1+ TIL phenotypes, we found that CD27+ and CD28+ TIL
were preferentially expanded. The enrichment of CD27+ TIL during the four-week
period was very striking: increasing from 35% to 67% (Figure 4-4 B). The trend
toward CD27+ and CD28+ enrichment remained true in both IL-2 and IL-15
settings, but IL-15 always maintained the higher level of cells with such markers
(Figure 4-4 C).
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Fig. 4-3. IL-15 stimulation drives a better memory TIL response than IL-2.
TIL were initially stimulated for one week (until day 7) in the presence of IL-2 or
IL-15, followed by an additional three weeks of long-term expansion (until day28)
without further re-stimulation. In each case, TIL were harvested, counted, and
phenotyped by flow cytomtery staining at the end of the treatment. The plots
show the MART-1-specific TIL expansions. The two-tail Student t test was used
to determine the statistical significance of the difference between the IL-2 and IL15-supported expansions at day 28.
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Fig. 4-4. Memory TIL can be detected after stimulation and additional expansion.
In tests of TIL stimulation and expansion, at end of day 28 of culture, MART-1
tetramer staining was done, as was flow cytometry staining using the
differentiation markers CD27 and CD28. MART-1+ TIL were quantified and
compared between the IL-2 and IL-15 settings (A). In addition, tetramer-positive
TIL were analyzed for CD27 and CD28 expression by comparing expression
levels on day 0 and day 28 of MART-1-specific stimulation and expansion (B).
Subtle differences in these markers of memory cells were also found by
comparing the IL-2- and IL-15-supported TIL cultures (C), gated on the number
of total CD8+ TIL.
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IL-15 generated more-persistent memory CD8+ TIL
To investigate whether IL-15-generated memory CD8+ T cells differed from those
generated by IL-2, we compared the proliferation and apoptosis in the two
resulting TIL populations. After being stimulated for one week, TIL were cultured
for an additional three weeks. During the additional culture period, the cells were
closely monitored for their proliferation by staining for Ki-67, which is only
detectable during active phases of the cell cycle [281]. Higher levels of Ki-67
were consistently observed in IL-15-cultured TIL, both in the general CD8+
population and the antigen-specific MART-1+ population (Figure 4-5 A).
Apoptosis of TIL was examined at the end of the long-term culture (that is, on
day28) by quantitative real-time PCR. As shown in Figure 4-5 B, although the
anti-apoptosis gene Bcl-Xl was expressed at similar levels by the two populations,
expression of the pro-apoptotic gene Bim was almost two fold higher in IL-2cultured TIL than in IL-15-cultured TIL, indicating that the IL-15 rendered TIL less
vulnerable to apoptosis. Additionally, we examined two genes related to memory
CD8+ T cells. Eomesodermin has been reported to be highly expressed on
memory T cells [282], and we observed a higher level of expression of this gene
in IL-15-cultured TIL. LEF1 was originally reported to be a transcription factor
differentiating between naïve and antigen-experienced T cells. It was reported
that Wnt pathway maintains hematopoietic stem cells by promoting quiescence
and inhibiting proliferation [283]. LEF1 is the downstream effector of the Wnt
pathway and is downregulated upon TCR or IL-15 receptor engagement [283].
To our surprise, we observed a much lower level of LEF1 in IL-15-cultured TIL
than in IL-2-cultured TIL; suggesting IL-15 drives less activation of Wnt-βcatenin-LEF1/TCF-1 pathway. Overall, the evidence showed that IL-15, as
compared with IL-2, helps generate a superior memory status of CD8+ TIL.
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Fig. 4-5. IL-15 generated a superior population of memory CD8 T cells.
After TIL stimulation and expansion, MART-1 tetramer staining as well as Ki-67
intracellular staining was performed to monitor cell proliferation during the 3-week
long-term culture. As shown in (A), representative flow data revealed the
difference in proliferation between IL-2- and IL-15-cultured TIL. At the end of day
28, TIL were harvested and their RNA was converted to cDNA for quantitative
real-time PCR. The apoptosis-related genes Bcl-Xl and Bim and the memory T
cell markers Eomesodermin and LEF1 were examined (B). β-actin was also
included as an internal control and reference for calculations.
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Stimulation of memory T cells indicated their non-anergic status
Next, we investigated whether TIL cultured long-term could respond to antigen
restimulation. As shown in Figure 4-6, IL-2- and IL-15-stimulated TIL were still
able to expand upon DC and MART-1 restimulation, as shown by tetramer
staining and cell counts. This result indicated that the persisting memory TIL
were still reactive upon encountering antigen, instead of being anergic due to
some expression of an inhibitory signal, such as PD-1 or BTLA. Interestingly, TIL
stimulated with IL-15 had better viability, were larger, and contained more
granules than those stimulated by IL-2 (Figure 4-6 A). IL-15 support also
generated higher CD27, CD28 and GrB expression on MART-1+ TIL (Figure 4-6
B) and on other two TIL lines tested. Therefore, we specifically demonstrated that
IL-15 could better support TIL stimulation and long-term memory development
than IL-2. When the expansions of MART-1-specific TIL populations were
quantified and compared, we found that IL-15-supported TIL expanded 20- to 60fold after restimulation, while IL-2-supported TIL expanded no more than 20-fold
(Figure 4-6 C). These data are concordant with those from long-term cultures,
showing that TIL cultured in the presence IL-15 presented superior memory
characteristics. This observation reflected their early proliferation advantage,
reduced apoptosis, and higher expression of Eomesodermin.
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Fig. 4-6. Rechallenge of memory TIL revealed their maintenance of antigen
response.
At day 28 of TIL culture, a second round of mDCs pulse-treated with MART-1
were applied to test the TIL memory to an antigen rechallenge. The TIL were
harvested and examined 1 week later (day 35). IL-2 and IL-15 supported TIL
activation differently, as indicated by morphologic properties such as the size and
granularity of the cells (A). MART-1 tetramer staining could still be detected after
stimulation, although the two populations’ differentiation markers and cytolytic
ability were not the same (B). The tests were repeated and similar results
obtained in independent TIL lines. Absolute numbers of MART-1-specific TIL
were calculated, and their expansion over 4 weeks was plotted in (C).
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Discussion
The success of ACT for metastatic melanoma relies on its ability to confer tumor
antigen-specific T cells over long-term (that is, for years after the therapy is
complete). Various studies have been reported on the correlation of TIL
persistence after adoptive transfer and favorable clinical response in patients.
More efforts are trying to identify the characteristics of persistent TIL to improve
ACT [52, 53, 261, 262, 276]. IL-2 was approved for the treatment of melanoma
more than a decade ago [32, 164]. It was hypothesized by us that alternative
cytokine treatment may be able to improve the TIL function. In this report, we
provided novel evidence that IL-15 may be better than IL-2 to support TIL
activation and the development of memory response upon tumor antigen
encountering. It has to be noted that although we used pre-REP TIL to prove the
superior efficacy of IL-15 support, post-REP TIL were also tested and the same
conclusion holds true. Therefore, patients receiving ACT should have better
clinical response if IL-15 is used to replace IL-2 as cotherapy. In our study,
MART-1 antigen-specific stimulation and TIL expansion were tracked to compare
IL-15 with IL-2. This experimental design closely mimics the in vivo stimulation of
ACT using TIL. Our study strongly supports the clinical application of IL-15, in
place of IL-2, to support TIL used for ACT in vivo. Our results also suggest that
memory TIL characterized as CD27+ and CD28+ comprise the long-term
persistent population that is able to respond to antigen restimulation. In
accordance with our previous report, we also found that CD27+ and CD28+ TIL
may serve as a better set of markers to screen for persistent memory TIL than
the currently used analysis of IFN-γ secretion in response to autologous tumor.

To induce effective tumor control, Lou et al proved that vaccination of DC was
helpful in expanding the anti tumor T cell response [279]. This strategy is
currently being applied in a phase II clinical trial to investigate its efficacy on
patients. Numerous studies have suggested that IL-15 can be presented to T
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cells via IL-15Rα transpresentation [164, 208, 211, 278]. It was observed that IL15Rα is expressed on mature myeloid DCs generated by the ITIP cocktail, which
is used clinically and also in our experiments [211, 278]. These data provide solid
evidence for the application of IL-15 in vivo. It was observed that the cytokine
milieu is changed after a lymphodepletion regimen administered prior to adoptive
T cell transfer in melanoma patients [184]. Specifically, IL-15 and IL-7 were found
to be increased in the serum of patients. It is postulated that these homeostatic
cytokines, liberated from competition with endogenous lymphocytes, may be an
important factor for improved TIL persistence and better clinical response [184].
Logistically, recombinant IL-15 is beginning to be produced under Good
Manufacturing Practice (GMP) conditions for human clinical trials. This highly
advocated work was conducted by Dr. Thomas Waldmann (Metabolism Branch,
Center for Cancer Research) in conjunction with the Biopharmaceutical
Development Program, NCI [168, 284, 285]. DC vaccination can provide
sufficient IL-15Rα, on top of its ability of effective T cell priming and activation.
Therefore, IL-15 would be effective transpresented, when combined with DC
vaccination, to boost the population of infused TIL in vivo.

IL-15 shares the ß and common γ receptor chains with IL-2, but IL-15 acts
differently on T cells. For example, IL-15 inhibits AICD, which is usually promoted
by IL-2. IL-15 expands CD8+ memory T cells, while IL-2 participates in the
maintenance of peripheral CD4+ CD25hi regulatory T cells, which may hamper
the tumor control of infused TIL in ACT [8, 164, 168, 224, 277]. There have also
been observations that IL-15 restores telomerase activity and rescues nonresponsive T cells isolated from the tumor microenvironment [226, 286]. These
unique properties of IL-15 indicate its special role in tumor immunity. The
introduction of IL-15 in clinical trials is imminent. However, we still lack sufficient
knowledge of function and regulation of IL-15. For example, it is unknown how IL15 negates certain inhibitors or negative factors to promote T cell activation and
memory. This knowledge will guide us to better target responding T cell subsets
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or interfere with those negative factors to enhance tumor immunity. PD-1 [287]
and CTLA-4 [288] are notorious T cell inhibitory receptors, and several antibodies
have been developed to enhance anti tumor T cell response in their presence.
We found that a large percentage of our infused TIL express PD-1 and CTLA-4.
It will therefore be important to test how IL-15 support of TIL will affect these
receptor functions and how IL-15 will synergize with blocking antibodies, such as
ipilimumab (CTLA-4 blocking antibody), to improve tumor immunotherapy.

IL-15 has similar but subtle different signal pathways, partially due to its special
distribution and reverse signaling of IL-15Rα [211]. In addition, it has been
determined that IL-15 activates NF-κB and AP-1, as well as c-myc. Another
interesting finding is that the IL-15Rα chain is constitutively associated with the
receptor tyrosine kinase Axl [289, 290]. Activation of Axl subsequently activates
downstream PI3-K/Akt pathway and upregulates Bcl-2 and Bcl-XL. These unique
signatures of IL-15 may explain the differences between IL-2 and IL-15 in
supporting TIL [7].

The other hypothesis regarding the different but subtle roles of IL-15 as
compared with IL-2, in supporting TIL response and memory against antigen
restimulation can be raised, based on IL-15’s distinct fashion of transpresentation.
The cross-linking or gathering of IL-2/15 receptor β and γ by transpresentation
may result in some subtle difference in the recruitment of adaptor signaling
molecules. The IL-15 ligation may cluster more IL-2/15Rβγ dimerization than IL-2
ligation, therefore generating conformational or structural different patterns of
signaling imitation. To address this hypothesis, advanced imaging techniques,
such as two photon microscopy may be helpful.

Biologically, IL-15 and its unique receptor IL-15Rα are tightly regulated. At the
mRNA level, IL-15 is constitutively-expressed on various cell types and tissues.
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However, detection of IL-15 protein is mostly restricted to monocytes, epithelial
cells, DCs and fibroblasts [211]. The translation of IL-15 has several checkpoints:
its multiple AUG elements in the 5’-UTR, which attenuate the translation; its
signal peptide sequences rendering IL-15 production very inefficient; and its Cterminal coding sequence. It is estimated that removal of all three brakes can
boost IL-15 production 250-fold [211]. This tight regulation of IL-15 is to prevent
immune deregulation caused by excessive IL-15. Indeed, several autoimmune
inflammatory diseases have been indicated to have abnormal IL-15 expression
[291]. Furthermore, therapeutic interventions targeting IL-15 by soluble IL-15Rα,
antibodies specific to IL-15, or IL-15Rβ have been the focus of active research.
Additionally, there are some observations that membrane-bound IL-15 promotes
tumor cell growth, migration, invasion and angiogenesis [292-294]. This evidence
may not be strong because the observations were restricted to only certain tumor
types. However, the aforementioned immune deregulation and possible tumorpromoting effects of IL-15 have to be carefully examined in order to move cancer
therapeutics forward. Therefore, it is especially important in the setting of ACT to
determine the optimal dose of IL-15, which is necessary to boost TIL response
while not overdosed to prevent its side effects.

In conclusion, the results of our present study suggested prompt changes in
current approaches to cancer immunotherapy. Specifically, our findings argue for
the use of IL-15, instead of IL-2, to activate TIL in vivo. This modification can
improve in vivo tumor lysis in short-term and contribute to a larger pool of tumorreactive memory TIL, which in turn provide long-term anti-tumor response and
prevent melanoma relapse or metastasis in patients.
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Chapter 5

General discussions and Future directions
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Summary and discussion
Pre-clinical studies have helped greatly advance the field of ACT. Examples are
the introduction of lymphodepletion prior to the TIL infusion, and DC vaccination
to further boost TIL in vivo. In order to increase the response rates of ACT,
discovering ways to further improve TIL survival and function in vivo are needed.
Our experiments in this thesis revolved around the central theme in ACT that in
vivo reactivation of TIL by tumor antigens and persistence of TIL upon infusion is
critical for TIL anti tumor efficacy. Current ACT procedures include initial TIL
isolation from tumor fragment, ex vivo TIL expansion, REP, harvesting TIL and
infusion

and

patient

prior

conditioning

(lymphodepletion).

Given

the

immunological reality that memory CD8+ T cells further differentiate ex vivo
during extensive expansion, the REP as practiced today, using IL-2 may yield TIL
largely unable to further expand in vivo upon re-encountering antigen after
infusion into patients. The extensive expansion may cause unwanted terminal
differentiation and in turn, the loss of antigen specific memory T cells. Our initial
hypothesis was that the REP drives the TIL to further differentiate and become
hyporesponsive to antigen restimulation, therefore, proper cytokine treatment or
other ways to expand TIL is needed to improve upon this outcome.

In our studies, we found that the REP induces highly differentiated TIL that may
not be ideal for ACT. This result indicates that in the current practice of ACT, TIL
infused into patients may not be able to function and persist as expected,
especially after contact with melanoma antigens. We discovered two ways to
improve TIL responses. Firstly, the combination of IL-15 and IL-21 could
substitute for IL-2 in the REP to generate improved TIL products with strong
tumor antigen-specific responses, an improved effector-memory phenotype.
Moreover, the REP performed with the combination of IL-15 and IL-21 improved
post-REP TIL memory phenotype without compromising the cell yield. Secondly,
we found that IL-15 was superior to IL-2 in supporting the reactivation of CD8+
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TIL with the MART-1 melanoma antigen. IL-15 facilitated better antigen-specific
cytolytic ability and long-term memory maintenance than IL-2. Based on these
observations, we propose two modifications to the current ACT protocol. 1)
Substitute IL-2 REP with IL-15+IL-21 REP (using this method, less differentiated
populations of TIL can be used for infusion). 2) Administer IL-15 instead of highdose IL-2 following TIL infusion as a cotherapy for ACT, in order to support a
better memory CD8+ T cell response (Fig. 5-1). This also alleviates any concerns
regarding IL-2 driving any Treg expansion.

However, before testing the two modifications in clinical application, there are
some stringent pre-clinical studies to be conducted. Although a combination of
IL-15 plus IL-21 in the REP can maintain CD28 expression, their effect on other
important functional markers on CD8 memory T cells such as IL-7Rα, telomerase
reactivation, inhibitory KIRs, is unknown. Therefore, on basis of previous results
on Chapter 3, IL-15+IL-21 REP generated TIL can be compared with regular IL-2
REP generated TIL, for example by microarray analysis to reveal their gene
expression profiles. Further titration and optimization of this combined cytokine
cocktail maybe interesting to achieve the best outcome of TIL as well as reducing
reagent cost for clinical. Functional analysis and long-term memory response of
this novel REP generated TIL should also be tested. On the other hand, artificial
APCs, eg. K562 expressing certain tumor antigens and costimulatory ligand, may
be combined with IL-15+IL-21 for optimal ex vivo TIL expansion. The second
modification of IL-15 cotherapy instead of IL-2 deserves more careful studies. A
major aspect is how to efficiently deliver IL-15 to patients. IL-2 is given to patient
through i.v. infusion, and the dose stops at patients’ tolerance. The newly opened
NCI clinical trial of IL-15 also takes this route of administration. However, this
may raise concerns of 1) inefficient utilizing of IL-15 through whole body
distribution, instead of concentrating at tumor site, and 2) possible toxicity
induced by IL-15 functions on other tissue, such as endothelial cells to induce
vascular leak syndrome similar to IL-2’s side effect. Since DC vaccination is
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investigated in a phase II clinical trial here at MD Anderson, we can propose
some ways to used DC to deliver IL-15. Transpresentation by DC is the distinct
feature of IL-15 signaling. The possibility of pulsing DC with both antigenic
peptide (eg. MART-1) and recombined human IL-15 can be evaluated. However,
the rapid turn over of IL-15 on the surface of DC may restrict this application. The
alternative way to use DC is to stimulate it with certain cytokines in vitro to
upregulate the IL-15 expression. TNF-α can be one candidate to stimulate DC.

Overall, the current experimental design can be improved. Matured DC pulsed
with MART-1 peptide was used all through the studies. This cognate antigen
stimulation can provide much closer reflection of TIL in response to melanoma
antigenic encounter, especially compared with the OKT3 stimulation system used
by many other studies. In such case, the different T cell reactivation response
can be magnified, without overwhelmingly TCR triggering bypassing other
additional costimulation or coinhibition regulation. For example, in pre-REP and
post-REP TIL comparison experiment, 1 μg/ml of OKT3 was used. At this strong
stimulation, both types of TIL proliferated, in contrast to the dramatic difference of
proliferation in the DC stimulation system as described. It has to be pointed out
that, with OKT3 stimulation post-REP TIL still presented less proliferation and
much higher apoptosis (>80% of the culture), as compared to pre-REP TIL.
However, we have to admit that there are other optimal systems to be used to
evaluate TIL’s response against melanoma antigens. Autologous tumor cell lines
can be a better testing to TIL’s response. The advantages of using melanoma
cells instead of DC for stimulation include: 1) the antigen expression profiles will
be more comprehensive; 2) there is less concern about the antigen expression
level, ie. too much or too little antigen peptide loaded on DC; 3) many cytokines
or growth factors secreted by melanoma cells but not DC or vise versa can affect
the system dramatically. The logistical issue of obtaining autologous melanoma
cell lines and their matched TIL lines to conduct the experiment, was the main
reason we could not pursue this system for the studies. Another system we can
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propose to improve the studies is to use in vivo mice model. Humanized mice or
immune incompetent mice can be used to grow human melanoma tumors,
following which TIL can be infused for therapy. This model can be the best
reflection of human adoptive cell therapy. Indeed we tried RAG2-/-, γC-/- mice
model to track the in vivo persistence of TIL upon cotransfer with DC. The
surprising observation was that, as early as day 3 of adoptive transfer, the preREP TIL already could not be detected from circulating blood. A tumor bearing
immune comprised mice model may be suitable for such in vivo TIL tracking
experiment.

It was surprising to observe that CD28 loss is associated with the
hyporesponsiveness of post-REP TIL, but CD28 is not functionally important in
the TIL restimulation. From the microarray data, a whole family of inhibitory KIRs
are enriched on CD28- TIL. This may suggest that post-REP TIL is very
susceptible to the negative inhibition by the highly expressed inhibitive KIRs on
their surface. Therefore, blocking inhibitive KIRs signaling will be very interesting
to be tested for improving TIL’s response against antigen restimulation. There
remains another possibility regarding the hyporesponsiveness of post-REP TIL
upon antigen restimulation: negative regulatory cytokines production. Higher
level of IFN-γ secreted by post-REP TIL upon antigen restimulation may be a
suppressive factor to them. IFN-γ can induce a tryptophan catabolism enzyme,
indoleamine 2,3-dioxygenase (IDO) [295]. IDO degrades tryptophan into
kynurenine, which in turn suppresses CD8 effector T cell function and promotes
the differentiation of Tregs [296]. In a mouse model, IDO was found to be highly
elevated in the tumor microenvironment and administration of its inhibitor caused
a dramatic tumor regression. Further analysis showed 10 fold increase of the
intratumoral CD8+ to CD4+ Foxp3+ T cell ratio [297]. It is therefore interesting to
block INF-γ in our DC stimulation system to address whether this is the reason of
post-REP TIL’s hyporesponsiveness. Other possible negative regulatory
cytokines can be IL-10, NO. To address these cytokine questions, it will be
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helpful to conduct a comprehensive cytokine profiling of TIL, upon antigen
restimulation, such as Luminex assay.

We showed that different cytokines present during CD8+ T cell restimulation
could dramatically alter their costimulatory molecular expression. For example, in
the context of OKT3 stimulation, IL-15+IL-21 drove extensive cell expansion, and
maintained CD28 expression. This is a novel finding since previous studies failed
to evaluate the comprehensive aspects of T cell stimulation (eg, omitting the cell
number issue but focusing mainly on cell phenotype). In our experiments, it was
shown that IL-15, as compared to IL-2, increased CD28 expression but not CD27
on activated T cells over a long-term culture. The cross-talk between cytokine
and costimulation remains relatively less investigated and lacks systematic
evaluation. It will be very important to work out how these major cytokines and
costimulatory molecules cross-talk. The advantages of mapping this all out is that
one can pinpoint the best combination of cytokines and costimulation signals
within a specific context (eg, different diseases, vaccination vs. therapy, cell
subsets, as well as differentiation stages) for expected cellular responses.
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Fig. 5-1. ACT: New approach with less differentiated TIL and DC vaccination.
Based on the data from this thesis: 1). REP should be modified with IL-21 and IL15 to generate superior quality of TIL products for infusion; 2). IL-15, instead of
IL-2, to be administrated to patients for superior TIL support in vivo.
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Possible future studies
There are several interesting observations on early serials of studies, and they
may be followed up for development of future research projects.

1) CD28 transcription regulation by CKIIα and Nuc
Casein kinase II (CKII) is a ubiquitous serine/threonine kinase [298]. It is
composed of catalytic α subunit and regulatory β subunit [299]. CKII
phosphorylates a broad spectrum of downstream substrates, and is known to
play an important role in cell proliferation and transformation. Over-expression of
active CKII leads to T cell lymphoma and fibroblast transformation, while
inhibition of CKII results in cell cycle blockade and loss of proliferate potential
[300-302]. Studies have implicated a role of CKII is cellular senescence; this has
implications for CD28 modulation and T cell senescence. Cell senescence is
defined as irreversible cell growth arrest, which is well characterized in T cells
differentiated into end-stage effector cells. Features of senescence include
telomere erosion, oligoclonal expansion and deregulated function [132, 303].
Interestingly, loss of CD28 expression is also a key marker associated with loss
of proliferate potential in human T cells [132]. CKII activity has been found to be
a regulator of cell senescence [304]. Induction of senescence naturally (through
Hayflick limit) leads to cell senescence correlated with transcriptional downregulation of CKII. Treatment with CKII inhibitors or siRNA knocking down CKII
function induces pre-mature cell senescence [304]. Moreover, transcription
factors needed for CD28 gene expression, such as Nuc, are targets of CKII. This,
together with the association of loss of T cell proliferate potential (senescence)
with CD28 loss, strongly suggests CKII may regulate CD28 expression in T cells
through Nuc modification.
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TNF-α, a prominent inflammatory cytokine, and CD80 ligation down-regulate
CD28 expression on T cells transcription. In contrast, IL-12 is shown to induce
CD28

expression.

Pioneering

work

by

Goronzy

and

colleagues

has

demonstrated that CD28 is regulated mainly at a transcriptional level at two
upstream sites by non-overlapping initiator elements called the αβ-INR [156].
Nuc and hnRNP-D0A are two proteins identified within CD28 α−INR binding
complex. It is plausible that during resting of post-REP TIL, Nuc and hnRNP-D0A
are conformationally activated and reinitiate CD28 transcription. Phosphorylation
of Nuc residues has been shown to be induced by CKII, cdc32, PKC and other
kinases during active cell cycle progression, which may negatively regulate CD28
transcription to fine-tune T cell activation. Nuc phosphorylation at certain Thr
residues induced by active cyclinB1 in HIV infected T cells has been implicated in
CD28 down-modulation. In contrast, dephosphorylation or alternative N terminal
residue phosphorylation could be responsible for CD28 gene upregulation. Since
CKII functional α subunit downregulation is associated with CD28 loss and T cell
senescence, therefore it is hypothesized that CKII is a critical kinase regulating
Nuc phosphorylation status for effective CD28 transcriptional initiation. Figure 5-2
illustrates the model for how TNF-α modulates CKII and Nuc regulation of CD28
transcription. In future, it will be interesting to test the link between CKII kinase
activity and Nuc phosphorylation and CD28 transcription.
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Fig. 5-2. Proposed model that CD28 transcription is regulated through nucleolin
phosphorylation mediated by CKII.
CD28 is regulated mainly at a transcriptional level. Two upstream sites are
binded by non-overlapping initiator elements and called the αβ-INR. TNF-α and
CD80 ligation downregulate CD28 expression on T cells. IL-12 induces CD28
expression. Nucleolin (Nuc) and hnRNP-D0A are two proteins identified within
CD28 α-INR binding complex. Phosphorylation of Nuc residues has been shown
to be induced by CKII during active cell cycle progression, which may negatively
regulate CD28 transcription to fine-tune T cell activation. CKII functional α
subunit down-regulation is associated with CD28 loss and T-cell senescence. It
is therefore hypothesized that CKII is a critical kinase regulating Nuc
phosphorylation status for effective CD28 transcriptional initiation.
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2) The role of TNF-α in the REP
Preliminary data suggested negating TNF-α in the REP culture would greatly
decrease the yield of expansion. Remicade added from day 0 of the REP can
block almost all the TNF-α present in regular REP, which peaked at about a
1,000 pg/ml concentration. In addition, the removal of TNF-α caused a nearly
90% decrease of the cell yield at end of the REP. If Remicade is added later,
such as day 2 or day 7 instead of day 0, or is decreased of its dose, a slight
recovery of the cell yield can be observed. This suggested that TNF-α may be an
important factor for the expansion of TIL. Further, the presence of TNF-α at the
very early stage of REP is critical. Therefore the hypothesis can be that TNF-α
presented at the initial activation of TIL during REP is critical for its later robust
expansion. The function of TNF-α maybe through indirect polarization of CD4 T
helper cells to secret more inflammatory Th1 cytokines to promote the whole
CD4 and CD8 T cells activation and proliferation. The absence of TNF-α may
negatively deprive T cells of this initial triggering. If the hypothesis is correct, the
next question then is where is the source of TNF-α in the REP? Because of its
relatively high amount and rapid appearance, TNF-α may be contributed by the
monocyte population from the irradiated feeder cells. Monocyte, which is the best
TNF-α secretor compared to T cells or other immune subsets, is responding to
irradiation stress by secreting TNF-α. The later increase of second wave TNF-α
may be contributed by the robustly expanding T cells. This issue is important to
be addressed because it maybe helpful to optimize the feeder cell composition in
order to achieve the best REP yield.

3) KIR as potential target for improving TIL response against antigen
restimulation
Inhibitory KIRs were found to be highly expressed by the CD28- TIL by
microarray analysis. The most striking observation was that KIR2DL family
members, from 1 to 5, all have enriched at CD28- TIL. Inhibitory KIRs function to
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suppress the activation and the cytotoxic activity of their expressing cells by
recognition of MHC ligands. The dominance of Inhibitory KIRs on CD28- TIL may
be the reason why they are hyporesponsive to antigen restimulation. In addition,
this implies, in clinical setting, that Inhibitory KIRs maybe a major activation
barrier preventing infused TIL from being activated, since on average over 70%
of post-REP TIL are CD28-. To address the question, either knocking down
Inhibitory KIRs on CD28- TIL or blocking KIR interaction should be experimentally
investigated. Since there are several members of KIRs, it may not be feasible to
design common sequence to knock down inhibitive KIRs. However, it is definitely
worthy of try, especially considering the current hot topics of siRNA or shRNA as
therapeutic agents. The other possibility is to use antibody or chemicals to block
the interaction of Inhibitory KIRs and their corresponding ligands.

4) Blocking PD-1 to improve TIL response against antigen restimulation
PD-1 has actually been extensive investigated on its targetability for cancer
immunotherapy. Two commercially fully humanized antibodies have been
evaluated on phase I clinical trials with multiple types of solid tumor patients
enrolled. These current clinical investigations of PD-1 are antibody therapy alone,
ie monotherapy. The observation in my study is very suggestive for the proposal
of combined therapy of ACT and anti-PD-1 (Figure 5-3). The isolation and ex vivo
expansion of optimal anti tumor TIL can be further enhanced by the
administration of anti-PD-1 treatment. This statement is very straightforward and
only requires minimal laboratory data to validate. However, the key problem, also
very practical, is how to obtain a functional blocking clone of antibody for
laboratory test and clinical application without business or regulatory concerns.

Overall, this thesis provided experimental evidences for two major modifications
over current ACT treatment. Using IL-15+IL-21 as supporting cytokines in the
REP, or/and administration of IL-15 instead of IL-2 after TIL infusion, may
enhance the anti-tumor efficacy and long-term persistence of infused T cells in
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vivo. In addition, there are some interesting topics being initiated for future
studies, such as CD28 transcriptional regulation and inhibitory KIRs blocking.
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Fig. 5-3. PD1+ TIL cannot proliferate in responding to antigen stimulation.
For post-REP TIL restimulation, mature DC was generated and used to present
MART-1 peptide. B7H1 (PD-L1) and B7DC (PD-L2) were co-stained with other
important DC markers, such as CD11c, CD80, and CD86 (A). After seven days
of DC stimulation, post-REP TIL was harvested and their MART-1 reactivity was
quantified by MART-1 tetramer staining (B). CFSE was used to study TIL
proliferation during the stimulation. FlowJo software generated different
generation of TIL based on their CFSE fluorescent intensity. Each generation of
TIL was then analyzed for their expression of PD-1 (C).
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Chapter 6

Materials and Methods

-151-

Patient TIL samples and REP
TIL from HLA typed metastatic melanoma patients were obtained following
research protocols approved by IRB of University of Texas M. D. Anderson
Cancer Center. Briefly, tumor resects were processed freshly into small pieces of
3- to 5-mm2 and plated into T cell culture media supplied with 6,000 IU/ml IL-2
(Proleukin, Novartis, East Hanover, NJ). While TIL grew out of tumor fragments,
cultures were counted and re-plated in order to maintain cell density around
2X106/ml. IL-2 was also given along with media change. After ~4-5 weeks,
>40X106 TIL were harvested and phenotyped for further study. We term this
phase of TIL “pre-REP” TIL. An important criteria for inclusion of TIL is their being
stained for CD8 expression, recognition of the MART-1 peptide tetramer (HLAA2.1 restricted), and other T cell differentiation markers.

REP (rapid expansion protocol) was conducted strictly following clinical
procedure, originally designed and validated by Riddell and Greenberg from Fred
Hutchson Cancer Center, Seattle. In detail, 30ng/ml OKT3, 6,000IU/ml IL-2 and
at least three different allogenic PBMC (Gulf Coast Blood Bank, Houston, TX.
and irradiated at 5,000cGy) were used to expand TIL. T cell/TIL culture media
(TIL-CM) was mixed with AIM-V (Invitrogen) at 1:1 ratio for use in REP. 1.3×105
was usually the start TIL number for rapid expansion. The whole culture started
from 20ml of volume and was set up in a T-25 flask with head up to create good
cell to cell contact. During two weeks of expansion, TIL were frequently counted
and diluted to 2 × 106/ml to prevent over-growth of cells. Each time, fresh IL-2
and TIL-CM + AIM-V were used to split the cell culture. Typically 1,000 fold
expansion was achieved after REP, meaning around 100 million of TIL from each
initial T-25 flask. TIL after the REP were termed “post-REP” TIL.

In some

experiments, IL-2 was substituted with 100 ng/ml IL-15 (R&D Systems,
Minneapolis, MN), or 100 ng/ml IL-21 (BioVision, Mountainview, CA), or a
combination of IL-15 (100 ng/ml) and IL-21 (100 ng/ml), at all steps in the REP.
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Cell culture media, peptides, cytokines and functional antibodies
T cell/TIL culture media consisted of Iscove’s modified Dulbecco’s medium
(Invitrogen, Carlsbad, CA) supplemented with 5% human AB serum (Gemini Bioproducts, West Sacramento, CA), 100U/ml Pen/Strep, 50ug/ml Gentamycin, and
50μM β-mercaptoethanol (2-ME) (all three from Invitrogen, Carlsbad, CA). T2
cells were maintained in regular RPMI-1640 media (Invitrogen, Carlsbad, CA)
supplied with 10% FCS (Sigma Aldrich, St. Louis, MO) and above listed
antibiotics and anti-oxidant (Invitrogen, Carlsbad, CA). Cytokines of GM-CSF, IL4, ITIP cocktail components (IL-β, TNF-α, IL-6, and PGE-2) for DC generation
were obtained from R&D system, Minneapolis, MN. The MART-1 peptide 27L
(ELAGIGILTV) and non-specific HIV rev peptide (SLYNTVATL) were synthesized
by Sigma Aldrich and stocked in -80C. Recombinant protein CTLA-4-Ig, blocking
antibodies against CD80 and CD86 were bought from R&D system, and
validated following product data sheet for their function test. Remicade
(infliximab) was obtained from Johnson & Johnson, New Brunswick, NJ.

Flow cytometry antibodies, and analysis and sorting of TIL
TIL were stained for human T-cell differentiation markers using fluorochromeconjugated monoclonal antibodies recognizing CD3, CD4, CD8, CD25, CD27,
CD28, CD45RA, CD57, CD62L, HLA-A2, CD70, CD80, CD83, CD86, and
obtained from BD Biosciences (San Jose, CA) or eBiosciences (La Jolla, CA).
TIL were also stained with HLA-A2.1 MART-1 peptide (ELAGIGILTV) tetramer
(Beckman Coulter, Fullerton, CA) to track the changes of the CD8+ MART-1–
specific subpopulation.

With some experiments, pre-REP and post-REP TIL

were also stained for CD25 (IL-2Rα), CTLA-4, CD122 (IL-2Rβ), CD132 (IL-2Rγ),
OX-40, 4-1BB, Granzyme B, IFN-γ, and Ki-67 (all from BD Biosciences) and PD1 (BioLegend, San Diego, CA). TIL apoptosis was monitored by 7-aminoactinomycin D (7-AAD; Sigma Aldrich, St. Louis, MO) and Annexin V (BD
Biosciences) staining of CD8+ or CD8+ MART-1 tetramer+ subpopulations. The
stained cells were analyzed by using a BD FACScanto II flow cytometry analyzer
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and FACSDiva software. Data were further analyzed and presented by FlowJo
software (TreeStar, San Carlos, CA). In some experiments, either pre-REP or
post-REP TIL were subjected to flow cytometry cell sorting (FACS), using
FACSAria sorting machine (BD Biosciences) to differentiate CD8+CD28+ from
CD8+CD28- subpopulations, or CD8+CD27+ from CD8+CD27- subpopulations.

To give some example staining tubes:
(1) CD8-PerCP-Cy5.5,

CD57-FITC,

CD27-APC,

CD28-PE-Cy7,

control

CMV/HIV tetramer-PE
(2) CD8-PerCP-Cy5.5, CD57-FITC, CD27-APC, CD28-PE-Cy7, MART-1
tetramer-PE
(3) CD8-PerCP-Cy5.5, CD45RA-FITC, CD27-APC-Alexa 750, CD28-PE-Cy7,
control CMV/HIV tetramer-PE, IgG1-APC
(4) CD8-PerCP-Cy5.5, CD45RA-FITC, CD27-APC Alexa 750, CD28-PE-Cy7,
MART-1 tetramer-PE, Granzyme B-APC
(5) CD8-PerCP-Cy5.5, CFSE-FITC, CD27-APC-Alexa 750, CD28-PE-Cy7,
control IgG-PE, IgG-A647
(6) CD8-PerCP-Cy5.5, CFSE-FITC, CD27-APC Alexa 750, CD28-PE-Cy7,
CD107a-PE, IFN-γ-A647
(7) CD8-PerCP-Cy5.5, CFSE-FITC, CD27-APC-Alexa 750, CD28-PE-Cy7,
control CMV/HIV tetramer-PE, IgG1-A647
(8) CD8-PerCP-Cy5.5, CFSE-FITC, CD27-APC Alexa 750, CD28-PE-Cy7,
MART-1 tetramer-PE, GranzymeB-A647

DC generation and maturation, and re-stimulation of TIL with MART-1 peptide–
pulsed mature DC
Human DC were generated from plastic adherent monocytes obtained from HLAA2.1+ normal donors’ peripheral blood (obtained from the Gulf Coast Regional
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Blood Bank, Houston, TX) in T-75 flasks. These DC were differentiated with
1,000 U/ml GM-CSF and 1,000 U/ml IL-4 (R&D Systems, Minneapolis, MN). DC
culture media was Iscove’s modified Dulbecco’s medium supplied also with
Glutamax, 2% human AB serum, 1X Pen-Strep, and 50 μM 2-mercaptoethanol
(designated as DC-CM). After 5 days, the DC were matured through exposure to
a cocktail of IL-1β, TNF-α, IL-6, and PGE-2 (ITIP) [280]. The mature DC (mDC)
were irradiated at 2,000 cGy and then pulsed with 3 μg/ml of MART-1 peptide for
1.5 hours. 2×106 TIL in 24-well plates were re-stimulated by adding 2×105 MART1 peptide-pulsed mature DC in TIL-CM. HIV rev peptide pulsed mDC were used
as control for TIL stimulation. 200 U/ml IL-2 was provided on day1 of the
stimulation and half dose of IL-2 supplied again at day4. The culture lasted for 78 days followed by phenotypical and functional analysis of TIL upon stimulation.

Caspase3 Cleavage CTL assay
We used a highly sensitive flow cytometry-based CTL assay measuring the
cleavage of caspase 3 in target cells as readout. In essence, target cells (T2
cells) were first labeled with DDAO-SE (Molecule ProbeTM, Invitrogen, Carlsbad,
CA), cell trackers dye whose fluorescence exciting/emission profile is similar to
APC. Then peptides pulsing were conducted with 5 μM concentration in low
serum (2%) TIL-CM at 37oC for one hour, which was then followed by three times
wash. CTL reaction was set up with TIL as effector cells at different E:T ratios for
3-4 hours. At end of CTL reaction, cells were harvested and permeabilized using
Perm/Fix reagent (BD Biosciences, San Jose, CA). A staining procedure with the
antibody recognizing cleaved caspase 3 was conducted to monitor target cell
apoptosis. Results were process on flow cytometry machine and analyzed with
FlowJo.
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CFSE labeling
1 μM of CFSE (Molecule ProbesTM/Invitrogen, Carlsbad, CA) was used for
labeling cells to monitoring their proliferation. This cell trackers dye has a
fluorescence exciting/emission profile similar to FITC. The proliferating cells can
dilute CFSE and generate proliferation curves in 7 day stimulation experiments.
TIL were first washed in PBS and resuspended in PBS containing CFSE.
Labeling was done in room temperature for 5-7 minutes followed by three time of
wash with TIL-CM. Stimulation was next set up as described earlier, and CFSE
dilution was measured with Flow cytometry FITC channel.

IFN-γ intracellular staining and IFN-γ cytokine detection by MSD system
Target cells were first peptides pulsed, which was with 5 μM concentration in low
serum (2%) T cell media at 37C for one hour, followed by three times wash.
MART-1 and HIV rev peptide pulsed T2 cells were used respectively, as positive
or negative target. CTL co-culture was set up with TIL (500,000 per tube) as
effector cells at different E:T ratios for 5-6 hours. At 1 hour of CTL, GolgiStop (BD
Biosciences, San Jose, CA) was added to retain newly synthesized cytokines. At
end of CTL, cells were collected and stained after permeabilization with IFN-γ
Abs.

Alternatively, to detect the IFN-γ secreted in culture supernatant, similar CTL coculture was set up but with less TIL (25,000 per tube) and longer culture time
(over night). An effector-to-target (E:T) ratio of 1:1 was used and T2 cells pulsed
with MART-1 or HIV rev peptide were used as target cells. The CTL co-culture
did not contain GolgiStop since IFN-γ was not measured by intracellular staining.
Harvest supernatant was then incubated with IFN-g recognizing primary antibody.
The recognition of IFN-γ was further amplified and quantified by the biotinstreptavadin interaction and the Alkaline Phosphatase-BCIP/NBT Colorimetric
reaction.
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Luminex assay for cytokine profile of REP
The essence of Luminex is to monitor the spectral properties of pre-designed
beads, thus identify cytokine types, while simultaneously measuring the amount
of

fluorescence

associated

with

R-phycoerythrin

for

cytokine

amount.

Customized cytokine panel from Bio-Rad (Hercules, CA) includes: IFN-γ, IL-2, IL4, IL-5, IL-10, IL-13, TNF-α, and GM-CSF. The standard curves for each cytokine
were obtained with the reference cytokine supplied within the kit. Culture media
supernatants were diluted 1:1 with appropriate assay dilute. A 96-well filter plate
was specially used for the assay, with all incubation steps in the dark and at
room temperature. In brief, the following procedure was conducted: firstly, prewet the filter plate with 200 μL of working washing solution. This solution was
removed by aspiration from the plate bottom using a vacuum. 25 μL of the
multiplex beads were pipetted into each well and the filter plate washed two
times. Incubation buffer (50 μL) and diluted samples or standards (50 μL) were
pipetted into the wells with following 2 hours incubation with the beads.
Thereafter, the plate was washed and detector antibody conjugated to biotin was
added. After 1 hour incubation, the plate was washed again followed by 30
minutes incubation with streptavidin conjugated to R-phycoerythrin (StreptavidinRPE). After removing the unbound Streptavidin-RPE, the beads were analyzed in
the Luminex 100 instrument (Applied Cytometry Systems, Dinnington, UK). Raw
data of mean fluorescence intensity (MFI) were analyzed and then converted into
cytokine concentrations.

Fluorescence Telomere length assay
Quantitative flow-FISH was shown to measure the average length of telomere
repeats at chromosome ends in individual T cell, as previously described. FITCconjugated telomere probe (FITC-OO-CCCTAACCCTAACCCTAA, O indicating a
molecule linking FITC to DNA sequence) was obtained from Dako (Carpinteria,
CA). And FITC-labeled fluorescent calibration beads (Quantum TM-24 Premixed;
Bangs Laboratories, Fishers, IN) were used to convert telomere fluorescence
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data to molecules of equivalent soluble fluorescence (MESF) units. The equation
of “bp = MESF X 0.495” was used to estimate the telomere length in base pair
from telomere fluorescence in MESF units. Aliquots of the K562 cell line
(standard telomere length ~4.0-4.5KB) were used as daily positive control to
normalize telomere lengths. Non-specific sequenced probes were included as
negative controls.

Microarray experiment and analysis
Post-REP TIL were freshly harvested from the flasks and sorted after anti-CD4
and anti-CD28 staining into two subsets, CD4-CD28+ and CD4-CD28-. After a 3-h
rest period to shed staining antibodies after sorting, TIL were processed with the
RNeasy kit (Qiagen, Valencia, CA) to obtain RNA for microarray analysis.
Samples (1 μg) of RNA were subjected to reverse transcription and probe
blotting using an Illumina kit, which uses a human Ref6 chip (Illumina, Inc., San
Diego, CA). Image acquisition and data processing, conducted with BeadStudio
software (Illumina, Inc.), generated a set of genes (detected with a p-value <0.01)
as well as data from supervised group analysis. Microarray data sets were
explored further using a heatmap server (http://noble.gs.washington.edu/prism/)
and Onto-Tool (12; http://vortex.cs.wayne.edu/projects.htm). Real-time PCR was
conducted to validate key genes of interest.

Quantitative real-time PCR
Quantitative real-time PCR was used to measure the expression of the
apoptosis-related genes and marker genes for memory CD8 T cells. Using the
Qiagen RNeasy Mini Kit, we isolated RNA from TIL cultured long-term in medium
with or without IL-2 or IL-15. The RNA was converted to cDNA using the
SuperScript III First-Strand Synthesis System according to the manufacturer’s
instructions (Invitrogen). After the cDNA was obtained, the PCR reactions were
visualized with iQTM SYBR Green Supermix (BioRad, Berkeley, CA) run in an
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iCycler (BioRad, Berkeley, CA) using the following program: 95°C for 30 minutes
(denaturation); 60°C for 30 minutes (annealing); and 72°C for 30 minutes
(elongation). The primers used were as follows:
Bcl-Xl:
forward 5'-TGAGTCGGATCGCAGCTTGG,
reverse 5'-TGGATGGTCAGTGTCTGGTC;
Bim:
forward 5'-ACAGGAGCCCAGCACCCATG,
reverse 5'-ACGCCGCAACTCTTGGGCGA;
LEF1:
forward 5'-GCCTCTACAACAAGGGACCCTC,
reverse 5'-TGTGTGACGGGTGTGATCCTGG;
Eomesodermin:
forward 5'-TGTGTTCGTAGAGGTGGTGCTG,
reverse 5'-TGTCTCATCCAGTGGGAACCAG;
β-Actin:
forward 5'-TTGCCGACAGGATGCAGAA,
reverse 5'-GCCGATCCACACGGAGTACT.

Statistics
Data were processed through Microsoft Excel, and Student t test was used to
analyze statistical differences between groups. A cut-off value of 0,05 was used
to determine significance of the statistics.
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